[go: up one dir, main page]

HK1215170A1 - 治療精神分裂症的方法和組合物 - Google Patents

治療精神分裂症的方法和組合物 Download PDF

Info

Publication number
HK1215170A1
HK1215170A1 HK16103149.6A HK16103149A HK1215170A1 HK 1215170 A1 HK1215170 A1 HK 1215170A1 HK 16103149 A HK16103149 A HK 16103149A HK 1215170 A1 HK1215170 A1 HK 1215170A1
Authority
HK
Hong Kong
Prior art keywords
compositions
methods
treating schizophrenia
schizophrenia
treating
Prior art date
Application number
HK16103149.6A
Other languages
English (en)
Inventor
Michela Gallagher
Original Assignee
The Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Johns Hopkins University filed Critical The Johns Hopkins University
Publication of HK1215170A1 publication Critical patent/HK1215170A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HK16103149.6A 2012-11-14 2013-11-14 治療精神分裂症的方法和組合物 HK1215170A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261726440P 2012-11-14 2012-11-14
US61/726,440 2012-11-14
PCT/US2013/070144 WO2014078568A1 (en) 2012-11-14 2013-11-14 Methods and compositions for treating schizophrenia

Publications (1)

Publication Number Publication Date
HK1215170A1 true HK1215170A1 (zh) 2016-08-19

Family

ID=50731694

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16103149.6A HK1215170A1 (zh) 2012-11-14 2013-11-14 治療精神分裂症的方法和組合物

Country Status (6)

Country Link
US (3) US10154988B2 (zh)
EP (2) EP3610890A1 (zh)
JP (2) JP6440625B2 (zh)
CA (1) CA2891122C (zh)
HK (1) HK1215170A1 (zh)
WO (1) WO2014078568A1 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1215170A1 (zh) 2012-11-14 2016-08-19 The Johns Hopkins University 治療精神分裂症的方法和組合物
WO2014144663A1 (en) * 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
PH12021552653A1 (en) * 2014-01-21 2023-07-17 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
HUE045610T2 (hu) 2014-01-21 2020-01-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait vagy ortosztérikus agonistáit tartalmazó kombinációk és alkalmazásuk
KR101634440B1 (ko) 2014-08-21 2016-06-30 서울대학교산학협력단 AMPA 수용체 GluA1의 인산화 억제제를 포함하는 정신질환의 예방 또는 치료용 약학조성물
EA034167B8 (ru) 2015-05-22 2021-04-27 Эйджинбайо, Инк. Фармацевтические композиции леветирацетама пролонгированного высвобождения
WO2017195144A1 (en) * 2016-05-12 2017-11-16 Jubilant Generics Limited Pharmaceutical compositions comprising brivaracetam
CN106109402A (zh) * 2016-07-20 2016-11-16 南通雅本化学有限公司 一种左乙拉西坦注射液
MX382132B (es) 2016-12-20 2025-03-13 Lts Lohmann Therapie Systeme Ag Sistema terapeutico transdermico que contiene asenapina y polisiloxano o poliisobutileno
KR102506333B1 (ko) * 2016-12-20 2023-03-06 에르테에스 로만 테라피-시스테메 아게 아세나핀을 함유하는 경피흡수 치료 시스템
US11253173B1 (en) * 2017-05-30 2022-02-22 Verily Life Sciences Llc Digital characterization of movement to detect and monitor disorders
CN110799180A (zh) 2017-06-26 2020-02-14 罗曼治疗系统股份公司 含阿塞那平和硅氧烷丙烯酸杂化聚合物的经皮治疗系统
WO2019243432A1 (en) 2018-06-20 2019-12-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
PL3810100T3 (pl) 2018-06-20 2025-05-12 Lts Lohmann Therapie-Systeme Ag Transdermalny system terapeutyczny zawierający asenapinę
BR112023000423A2 (pt) * 2020-07-10 2023-03-14 Agenebio Inc Combinações de agonistas gabaa alfa 5 e inibidores de sv2a e métodos de uso no tratamento de comprometimento cognitivo

Family Cites Families (731)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US759A (en) 1838-05-30 Reacting watek-wheels
US5516A (en) 1848-04-18 Combining lantebns and lamps
US1015498A (en) 1911-03-01 1912-01-23 Edward L Kraus Folding-desk blackboard.
IT535124A (zh) 1952-09-20
GB1039113A (en) 1964-08-06 1966-08-17 Ucb Sa New n-substituted lactams
GB1309692A (en) 1970-02-13 1973-03-14 Ucb Sa N-substituted lactams
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
JP2000319257A (ja) 1969-01-06 2000-11-21 Eisai Co Ltd １−ベンジル−４−［（５，６−ジメトキシ−２−フルオロ−１−インダノン）−２−イル］メチルピペリジン
US3953603A (en) 1973-11-05 1976-04-27 Eli Lilly And Company Hexahydro-dibenzo[b,d,]pyran-9-ones as psychotropic, particularly anti-depressant drugs
US4018895A (en) 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
IT1045043B (it) 1975-08-13 1980-04-21 Isf Spa Derivati pirrolidinici
NL7605526A (nl) 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
IT1075280B (it) 1977-02-11 1985-04-22 Isf Spa Procedimento per la preparazione di derivati pirrolidinici
BE864269A (fr) 1977-03-03 1978-06-16 Parke Davis & Co Nouveaux n-(aminoalkyl substitue)-2-oxo-1-pyrrolidine-acetamides et procedes pour les produire
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
EP0005689B1 (fr) 1978-05-08 1981-03-18 U C B, S.A. Nouveaux acides lactame-N-acétiques et leurs amides, leurs procédés de préparation et compositions thérapeutiques
US4654370A (en) 1979-03-12 1987-03-31 Abbott Laboratories Glyceryl valproates
US4352807A (en) 1979-07-30 1982-10-05 Pfizer Inc. Hexahydro-trans-pyridoindole neuroleptic agents
US4337250A (en) 1979-07-30 1982-06-29 Pfizer Inc. Hexahydro-trans- and tetrahydropyridoindole neuroleptic agents
US4431649A (en) 1979-07-30 1984-02-14 Pfizer Inc. Hexahydro-trans- and tetrahydropyridoindole neuroleptic agents
US4465683A (en) 1979-09-14 1984-08-14 Mead Johnson & Company Anti-psychotic agents
US4254124A (en) 1979-09-24 1981-03-03 Mead Johnson & Company Antidepressant agent
US4372960A (en) 1980-12-12 1983-02-08 Warner-Lambert Company Quaternary derivatives of N-(substituted-aminoalkyl)-2-oxo-1-pyrrolidine-acetamides as cognition activators
US4427679A (en) 1981-01-16 1984-01-24 Pfizer Inc. Hexahydro-trans- and tetrahydropyridoindole neuroleptic agents
FR2515179A1 (fr) 1981-07-24 1983-04-29 Hoffmann La Roche Derives de pyrrolidine, leur procede de preparation, les intermediaires pour leur synthese et leur application therapeutique
US4415085A (en) 1981-12-21 1983-11-15 Eli Lilly And Company Dry pharmaceutical system
PT77267B (en) 1982-09-07 1986-03-21 Lilly Co Eli Improved process for preparing novel octahydrobenz <f> isoquinolines or compounds relating thereto
PT77268B (en) 1982-09-07 1986-03-21 Lilly Co Eli Improved process for preparing novel bridged hexahydrobenz <f> isoquinolines or compounds relating thereto
US4977178A (en) 1982-09-20 1990-12-11 Pfizer Inc. Method of treating anxiety and depression with 1-phenyl-2(1H,3H)-indolone psycho-therapeutic agents
US4476307A (en) 1982-09-20 1984-10-09 Pfizer Inc. Heteroylidene indolone compounds
US4879391A (en) 1982-09-20 1989-11-07 Pfizer Inc. 1-Phenyl-2(1H,3H)-indolone psychotherapeutic agents
US4495187A (en) 1982-10-18 1985-01-22 Pfizer Inc. Method of using [1,2,4]triazolo[4,3-a]quinoxaline-4-amine derivatives as antidepressant and antifatigue agents
IL67623A (en) 1983-01-05 1984-09-30 Teva Pharma 1'-ethoxycarbonyloxyethyl ester of valproic acid,its preparation and pharmaceutical compositions containing it
IL72381A (en) 1983-07-20 1988-03-31 Sanofi Sa Pharmaceutical composition based on valproic acid
US4547501A (en) 1983-09-02 1985-10-15 Pfizer Inc. Method of using [1,2,4]triazolo[4,3-a]quinoxaline-4-amine derivatives as antidepressant and antifatigue agents
US4599339A (en) 1983-09-26 1986-07-08 Eli Lilly And Company Use of pyrimido[4,5-g]quinolines in treating parkinsonism
US4558070A (en) 1983-10-26 1985-12-10 Abbott Laboratories Acid salts of valproic acid
US4605655A (en) 1984-03-06 1986-08-12 Bristol-Myers Company Antipsychotic 1-fluorophenylbutyl-4-(2-pyrimidinyl)piperazine derivatives
GB8412357D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
GB8412358D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
US4668687A (en) 1984-07-23 1987-05-26 Bristol-Myers Company Psychogeriatric 1-(2-pyrimidinyl)piperazinyl derivatives of 1-pyrrolidin-2-ones
US4593037A (en) 1984-07-26 1986-06-03 Pfizer Inc. 1,3-disubstituted piperidine compounds as neuroleptic agents
US4619930A (en) 1985-01-16 1986-10-28 Bristol-Myers Company Antipsychotic cyclic imide derivatives of 2-(4-butylpiperazin-1-yl)pyridines, compositions and use
US4913906B1 (en) 1985-02-28 2000-06-06 Yissum Res Dev Co Controlled release dosage form of valproic acid
IL74497A (en) 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE58370B1 (en) 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
US4656173A (en) 1985-04-24 1987-04-07 Bristol-Myers Company Antipsychotic benzisothiazole S-oxide compound
US4677104A (en) 1985-05-06 1987-06-30 Bristol-Myers Company Antipsychotic fused-ring pyridinylpiperazine derivatives
JPS6222785A (ja) 1985-07-23 1987-01-30 Sanwa Kagaku Kenkyusho:Kk 新規な２−オキソピロリジン化合物及びその塩、その製法並びにこれらを有効成分とする脳機能障害の予防及び治療剤
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
IT1190133B (it) 1986-06-19 1988-02-10 Chiesi Farma Spa Derivati di acido valproico e di acido (e)-2-valproenoico,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4757073A (en) 1986-09-30 1988-07-12 Bristol-Myers Company Antipsychotic cyclic imide derivatives of 2-(4-butylipiperazin-1-yl) pyridines, compositions and use
US4816456A (en) 1986-10-01 1989-03-28 Summers William K Administration of monoamine acridines in cholinergic neuronal deficit states
DD263531A5 (de) 1986-10-21 1989-01-04 ������@���Kk�� Verfahren zur herstellung von verbrueckten bicyclischen imidverbindungen
MX174210B (es) 1987-02-17 1994-04-28 Pfizer Procedimiento para la preparacion de compuestos arilpiperazinil-alquilenfenil-p-heterociclicos
MX173362B (es) 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4771053A (en) 1987-03-02 1988-09-13 Bristol-Myers Company Method for alleviation of primary depressive disorders
HU201906B (en) 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
EP0282959A3 (en) 1987-03-17 1989-05-31 Hoechst-Roussel Pharmaceuticals Incorporated Substituted 9-amino-tetrahydro-acridines and related compounds, a process for their preparation and their use as medicaments
DE3709230A1 (de) 1987-03-20 1988-10-06 Desitin Arzneimittel Gmbh Neues calciumsalz der valproinsaeure
IT1225462B (it) 1987-04-03 1990-11-14 Mediolanum Farmaceutici Srl Sali organici di derivati della fisostigmina
US4784998A (en) 1987-04-06 1988-11-15 Bristol-Myers Company 1,3,4-oxadiazole pyschotropic compounds
US5002955A (en) 1987-04-23 1991-03-26 Hoechst-Roussel Pharmaceuticals Inc. Fused heteroalkylene quinolinamines and use as cholinergic agents
JP2755403B2 (ja) 1987-05-04 1998-05-20 デイービス、ボニー アルツハイマー病の治療のための化合物
US5187165A (en) 1987-05-15 1993-02-16 Hoechst-Roussel Pharmaceuticals Inc. Memory enhancing and analgesic 1,2,3a,8,8a-hexahydro-3a,8(and 1,3a,8)-di(and tri)methylpyrrolo[2,3-b]indoles
US4931447A (en) 1987-06-15 1990-06-05 Eli Lilly And Company Cycloalkylamides of (8β)-1-alkyl-6-(substituted) ergolines
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
JPS6422883A (en) 1987-07-17 1989-01-25 Sanwa Kagaku Kenkyusho Co 1-pyrrolidine acetamide derivative, its salt, production thereof and prophylactic and remedial agent for cereral dysfunction containing said derivative and salt as active ingredient
EP0300111B1 (en) 1987-07-22 1991-10-16 Farvalsa AG A moisture stable solid valproic acid formulation and a method of preparing the same
IL87674A (en) 1987-09-08 1993-08-18 Lilly Co Eli Azabicycloalkyl esters and amides of heterocyclic acids, their preparation and pharmaceutical compositions containing them
US5364863A (en) 1987-09-08 1994-11-15 Eli Lilly And Company Specific 5-HT3 antagonists
US4880930A (en) 1987-11-30 1989-11-14 New James S Psychotropic acyclic amide derivatives
US4891375A (en) 1988-01-13 1990-01-02 Pfizer Inc. Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds
US4883795A (en) 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5001130A (en) 1988-02-18 1991-03-19 Bristol-Myers Company Psychotropic heterobicycloalkylpiperazine derivatives
US5238959A (en) 1988-04-08 1993-08-24 Eli Lilly And Company 3-phenyloxy-3-phenyl propanamines
US5242911A (en) 1988-06-17 1993-09-07 Pfizer Inc. Bridged bicyclic imides as anxiolytics and antidepressants
WO1990002552A1 (en) 1988-09-16 1990-03-22 Pfizer Inc. Antipsychotic 4-[4-(3-benzisothiazolyl)-1-piperazinyl]butyl bridged bicyclic imides
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
CA2000786C (en) 1988-11-07 1999-01-26 Cornelus G. M. Janssen 3-piperidinyl-1,2-benzisoxazoles
US5254556A (en) 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
US5158952A (en) 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
MX18467A (es) 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
US5153206A (en) 1988-12-02 1992-10-06 Pfizer Inc. Arylpiperidine derivatives
US4950658A (en) 1988-12-06 1990-08-21 Board Of Trustees Of Southern Illinois Univ. Method of medical treatment of Alzheimer's disease
IL93051A0 (en) 1989-01-17 1990-11-05 Hoffmann La Roche ((5-oxo-2-pyrrolidinyl)methyl)cyclohexaneacetamides,their preparation and pharmaceutical compositions containing them
WO1990007926A1 (en) 1989-01-20 1990-07-26 Pfizer Inc. 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines
FR2643556B1 (fr) 1989-02-27 1993-03-05 Sanofi Sa Composition pharmaceutique a liberation prolongee d'acide valproique
US4981870A (en) 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
GB8908085D0 (en) 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US5238945A (en) 1989-04-11 1993-08-24 H. Lundbeck A/S Method of treating psychoses
US4963689A (en) 1989-05-19 1990-10-16 Pfizer Inc. Heterocyclicguanidines as 5HT3 antagonists
US4914207A (en) 1989-05-09 1990-04-03 Pfizer Inc. Arylthiazolylimidazoles
DE69021645T2 (de) 1989-05-19 1996-02-22 Hoechst-Roussel Pharmaceuticals Inc., Somerville, N.J. N-(aryloxyalkyl)heteroarylpiperidine und -heteroarylpiperazine, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente.
US5364866A (en) 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
EP0403713A1 (en) 1989-06-22 1990-12-27 Merrell Dow Pharmaceuticals Inc. Novel acetylcholinesterase inhibitors
US5693668A (en) 1989-06-22 1997-12-02 Merrell Pharmaceuticals Inc. Acetylcholinesterase inhibitors
US5350747A (en) 1989-07-07 1994-09-27 Pfizer Inc Heteroaryl piperazine antipsychotic agents
WO1991000863A1 (en) 1989-07-07 1991-01-24 Pfizer Inc. Heteroaryl piperazine antipsychotic agents
IT1231477B (it) 1989-07-12 1991-12-07 Sigma Tau Ind Farmaceuti (pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti
US5006525A (en) 1989-07-24 1991-04-09 Eli Lilly And Company Dopamine agonists method
US4956368A (en) 1989-07-24 1990-09-11 Bristol-Myers Company Metabolites and prodrug formulations of 8-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione
US4999430A (en) 1989-07-31 1991-03-12 Warner-Lambert Company Derivatives of 1,2,3,4-tetrahydro-9-acrisinamine
DE3927049A1 (de) 1989-08-16 1991-02-21 Sandoz Ag Halogenalkyl-phenyl-ketone und deren hydrate, ihre herstellung und verwendung
US5387590A (en) 1989-08-30 1995-02-07 Pfizer Inc. Benzazabicyclic carbamates as novel cholinesterase inhibitors
US4914102A (en) 1989-09-28 1990-04-03 Hoechst Roussel Pharmaceuticals, Inc. N-aminocarbamates related to physostigmine, pharmacentical compositions and use
US5011841B1 (en) 1989-11-14 1994-09-06 Pfizer Treatment of depression
US5232929A (en) 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
WO1991009844A1 (en) 1990-01-04 1991-07-11 Pfizer Inc. Substance p antagonists
NZ237241A (en) 1990-03-02 1993-11-25 Pharmetrix Corp Method for increasing the storage stability of physostigmine
US5043341A (en) 1990-04-11 1991-08-27 Eli Lilly And Company N-(2-hydroxycyclopentyl)-1-isopropyl-6-methylergoline-8-carboxamides
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
AU648317B2 (en) 1990-06-01 1994-04-21 Pfizer Inc. 3-amino-2-aryl quinuclidines, process for their preparation and pharmaceutical compositions containing them
JP2807577B2 (ja) 1990-06-15 1998-10-08 エーザイ株式会社 環状アミド誘導体
JP2800953B2 (ja) 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
US5399565A (en) 1990-07-17 1995-03-21 Eli Lilly And Company Pyrazolidinone CCK and gastrin antagonists and pharmaceutical formulations therof
CA2086434C (en) 1990-07-23 1998-09-22 John A. Lowe, Iii Quinuclidine derivatives
US5102891A (en) 1990-07-23 1992-04-07 Hoechst-Roussel Pharmaceuticals Inc. 1-(substituted pyridinylamino)-1H-indol-5-yl substituted carbamates
US5264442A (en) 1990-08-13 1993-11-23 Hoechst-Roussel Pharmaceuticals Incorporated Carbamoyl-1-(pyridinylalkyl)-1H-indoles, indolines and related analogs
TW200462B (zh) 1990-09-27 1993-02-21 Hoechst Roussel Pharma
ES2071334T3 (es) 1990-09-28 1995-06-16 Pfizer Analogos de anillos fusionados de nitrogeno conteniendo heterociclos no aromaticos.
CA2091562C (en) 1990-10-15 2001-03-27 John Eugene Macor Indole derivatives useful in psychotherapeutics
US5578612A (en) 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
US5559129A (en) 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5190951A (en) 1990-10-19 1993-03-02 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
US5147881A (en) 1990-11-14 1992-09-15 Pfizer Inc 4-(1,2-benzisoxazolyl)piperidine antipsychotic agents
JP2965675B2 (ja) 1990-11-21 1999-10-18 エーザイ株式会社 （―）―１―ベンジル―４―〔（５，６―ジメトキシ―１―インダノン）―２―イル〕メチルピペリジンの製造方法
TW197435B (zh) 1990-11-22 1993-01-01 Takeda Pharm Industry Co Ltd
JPH04327532A (ja) 1991-01-31 1992-11-17 Bristol Myers Squibb Co 活動過剰を伴う注意力欠乏疾患の治療に使用する医薬製剤
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5157034A (en) 1991-02-27 1992-10-20 Pfizer Inc. Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines
ES2065175T3 (es) 1991-03-01 1995-02-01 Pfizer Derivados de 1-azabiciclo(3.2.2)nonan-3-amina.
US5334720A (en) 1991-03-07 1994-08-02 Fisons Corporation Diphenyl-1-(aminoalkyl)-2-piperidinone and -2-pyrrolidinone derivatives having anticonvulsant properties
US5750542A (en) 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
UA45944C2 (uk) 1991-03-28 2002-05-15 Ейсай Ко., Лтд Гетероцикло-циклічні похідні амінів або їх фармацевтично прийнятні солі, проміжні сполуки, фармацевтична композиція, спосіб інгібування холінестерази, спосіб одержання гетероцикло-циклічних похідних амінів
US5627178A (en) 1991-04-23 1997-05-06 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5817655A (en) 1991-04-23 1998-10-06 Eli Lilly And Company Methods of treatment using a thieno-benzodiazepine
US5817656A (en) 1991-04-23 1998-10-06 Eli Lilly And Company Mental disorders
US5104880A (en) 1991-05-01 1992-04-14 Mayo Foundation For Medical Education And Research Huperzine a analogs as acetylcholinesterase inhibitors
CA2067614C (en) 1991-05-02 2002-07-30 Eiichi Otomo Agent for improving dementia
US5716965A (en) 1991-05-22 1998-02-10 Pfizer Inc. Substituted 3-aminoquinuclidines
FR2677019B1 (fr) 1991-05-27 1994-11-25 Pf Medicament Nouvelles piperidines disubstituees-1,4, leur preparation et leur application en therapeutique.
DE9290063U1 (de) 1991-05-31 1994-02-24 Pfizer Inc., New York, N.Y. Chinuclidin-Derivate
US5106856A (en) 1991-06-07 1992-04-21 Hoechst-Roussel Pharmaceuticals Inc. [(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds
UA39168C2 (uk) 1991-06-20 2001-06-15 Пфайзер, Інк. Фторалкоксифенільні похідні піперидину або хінуклідину, що є антагоністами речовини p і фармацевтична композиція на їх основі
TW202432B (zh) 1991-06-21 1993-03-21 Pfizer
FR2679555B1 (fr) 1991-07-25 1993-11-19 Fabre Medicament Pierre Nouveaux derives de l'uree, leur preparation et leur application en therapeutique.
HUT66324A (en) 1991-07-29 1994-11-28 Warner Lambert Co Quinazoline derivatives as acetylcholinesterase inhibitors and pharmaceutical compositions containing them
IT1251166B (it) 1991-08-09 1995-05-04 Chiesi Farma Spa Derivati di geneserina,loro preparazione e composizioni farmaceutiche che li contengono
WO1993006099A1 (en) 1991-09-16 1993-04-01 Pfizer Inc. Fused tricyclic nitrogen containing heterocycles as substance p receptor antagonists
US5161533A (en) 1991-09-19 1992-11-10 Xomed-Treace Inc. Break-apart needle electrode system for monitoring facial EMG
US5246947A (en) 1991-09-23 1993-09-21 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino-1,2-benzisothiazoles and their use for treating depression
HUT71488A (en) 1991-09-25 1995-11-28 Pfizer Process for the production of neuroleptic 2-substituted perhydro-1-h-pyrido[1,2a]pyrazines and pharmaceuticals compositions containing the same
US5231093A (en) 1991-10-01 1993-07-27 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
TW263504B (zh) 1991-10-03 1995-11-21 Pfizer
CA2080536A1 (en) 1991-10-17 1993-04-18 John S. Ward Nicotinic activity of a series of arecolones and isoarecolones
US5710168A (en) 1991-10-23 1998-01-20 Pfizer Inc. 2-piperidino-1-alkanol derivatives as neuroprotective agents
FI942187L (fi) 1991-11-12 1994-05-11 Pfizer Asyklisiä etyleenidiamiinijohdannaisia aine P-reseptoriantagonisteina
WO1993011106A1 (en) 1991-11-25 1993-06-10 Pfizer, Inc. Indole derivatives
US5137894A (en) 1991-12-05 1992-08-11 New James S 4-(4-Piperidinyl-thieno[3,2-c]pyridine derivatives of n-alkylglutarimides
ES2042384B1 (es) 1991-12-26 1994-06-01 Boehringer Ingelheim Espana Procedimiento para obtener derivados bis-piridinicos.
US5622976A (en) 1991-12-31 1997-04-22 Fujisawa Pharmaceutical Co., Ltd. Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
CA2129732A1 (en) 1992-02-25 1993-09-02 Alain Martin Cytoprotective compositions containing pyruvate and antioxidants
TW288010B (zh) 1992-03-05 1996-10-11 Pfizer
US5569662A (en) 1992-03-23 1996-10-29 Pfizer Inc. Quinuclidine derivatives as substance P antagonists
RU2101283C1 (ru) 1992-04-07 1998-01-10 Пфайзер Инк. Производные индола или их фармацевтически приемлемые соли
US6380233B1 (en) 1992-04-07 2002-04-30 Pfizer Inc Indole derivatives as 5-HT1 agonists
DK0635015T3 (da) 1992-04-10 1997-03-17 Pfizer Acylaminoindolderivater som 5-Htl agonister
US5439930A (en) 1992-04-14 1995-08-08 Russian-American Institute For New Drug Development Biologically active n-acylprolydipeptides having antiamnestic, antihypoxic and anorexigenic effects
US5256664A (en) 1992-04-28 1993-10-26 Bristol-Myers Squibb Company Antidepressant 3-halophenylpiperazinylpropyl derivatives of substituted triazolones and triazoldiones
US20050256162A1 (en) 1992-05-05 2005-11-17 Pfizer Inc Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
ES2164657T3 (es) 1992-05-18 2002-03-01 Pfizer Derivados aza-biciclicos puenteados como antagonistas de la sustancia p.
IT1254996B (it) 1992-06-25 1995-10-11 Mediolanum Farmaceutici Srl Esteri amminoalchilcarbammici dell'eserolina atti all'impiego come anticolinesterasici e relativo procedimento di preparazione
AU4396193A (en) 1992-08-04 1994-03-03 Pfizer Inc. 3-benzylamino-2-phenyl-piperidine derivatives as substance p receptor antagonists
ATE208376T1 (de) 1992-08-19 2001-11-15 Pfizer Substituierte benzylamin-stickstoff enthaltende nichtaromatische heterocyclen
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5440023A (en) 1992-09-18 1995-08-08 Beckman Instruments, Inc. Method for making valproic acid derivatives
US5604241A (en) 1992-10-21 1997-02-18 Pfizer Inc. Substituted benzylaminoquinuclidines as substance P antagonists
US5837711A (en) 1992-10-28 1998-11-17 Pfizer Inc. Substituted quinuclidines as substance P antagonists
TW251284B (zh) 1992-11-02 1995-07-11 Pfizer
US5498610A (en) 1992-11-06 1996-03-12 Pfizer Inc. Neuroprotective indolone and related derivatives
ATE147385T1 (de) 1992-11-12 1997-01-15 Pfizer Chinuclidin derivat als substanz p antagonist
US6369074B1 (en) 1992-12-10 2002-04-09 Pfizer Inc. Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists
DK0675886T3 (da) 1992-12-10 2000-09-18 Pfizer Aminomethylensubstituerede ikke-aromatiske heterocykler og deres anvendelse som substance P-antagonister
US5352459A (en) 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
TW444018B (en) 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
EP0674641B1 (en) 1992-12-17 1999-03-03 Pfizer Inc. Pyrrolopyrimidines as crf antagonists
EP0611769A1 (en) 1993-02-16 1994-08-24 Merrell Dow Pharmaceuticals Inc. Silylated acetylcholinesterase inhibitors
AU4982293A (en) 1993-03-02 1994-09-26 Fujisawa Pharmaceutical Co., Ltd. Novel heterocyclic compound
DE69318854T2 (de) 1993-03-04 1998-10-08 Pfizer Spiroazacyclischderivate als substanz p antagonisten
DE69427289T2 (de) 1993-03-16 2001-09-06 Pfizer Inc., New York Naphtalinderivate
IL109646A0 (en) 1993-05-19 1994-08-26 Pfizer Heteroatom substituted alkyl benzylamino-quinuclidines
EP0627400A1 (en) 1993-06-04 1994-12-07 Merrell Dow Pharmaceuticals Inc. Aromatic acetylcholinesterase inhibitors
SE9302080D0 (sv) 1993-06-16 1993-06-16 Ab Astra New compounds
US5869499A (en) 1993-07-15 1999-02-09 Pfizer Inc Benzyloxyquinuclidines as substance P antagonists
AU686654B2 (en) 1993-08-31 1998-02-12 Pfizer Inc. 5-arylindole derivatives
EP1209157A1 (en) 1993-09-17 2002-05-29 Pfizer Inc. Heteroarylamino and heteroarylsulfonamido substituted 3-benzylaminomethyl piperidines and related compounds
US6083943A (en) 1993-09-17 2000-07-04 Pfizer Inc Substituted azaheterocyclecarboxylic acid
GB9319732D0 (en) 1993-09-24 1993-11-10 Ucb Sa Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
US5468733A (en) 1993-09-30 1995-11-21 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU699465B2 (en) 1993-12-29 1998-12-03 Pfizer Inc. Diazabicyclic neurokinin antagonists
AU692530B2 (en) 1994-03-02 1998-06-11 Merck Sharp & Dohme B.V. Sublingual or buccal pharmaceutical composition
DK0757685T3 (da) 1994-04-29 2004-10-25 Pfizer Hidtil ukendte, acycliske og cycliske amider som midler til forögelse af frigivelsen af neurotransmitter
PL181895B1 (pl) 1994-06-16 2001-10-31 Pfizer Nowe pirazolo-i pirolopirydyny _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ PL PL PL PL
US5744476A (en) 1994-06-27 1998-04-28 Interneuron Pharmaceuticals, Inc. Dopamine D1 agonists for the treatment of dementia
NZ284853A (en) 1994-06-29 1998-12-23 Pfizer 1-(azacycloalkyl)-7-(arylalkoxy)naphthalene derivatives; medicaments
MX9700693A (es) 1994-07-26 1997-04-30 Pfizer Derivados del 4-indol.
CZ290988B6 (cs) 1994-08-18 2002-11-13 Pfizer Inc. Deriváty fenolu a farmaceutický prostředek na jejich bázi
US5597826A (en) 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
US5627200A (en) 1994-09-26 1997-05-06 Pfizer Inc β3 -Adrenoceptor agonists and antagonists for the treatment of intestinal motility disorders, depression, prostate disease and dyslipidemia
WO1996010570A1 (en) 1994-09-30 1996-04-11 Pfizer Inc. NEUROLEPTIC 2,7-DISUBSTITUTED PERHYDRO-1H-PYRIDO[1,2-a]PYRAZINES
US5516759A (en) 1994-12-08 1996-05-14 Tap Holdings Inc. LHRH antagonists having lactam groups at the N-terminus
US5658590A (en) 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
US5741789A (en) 1995-01-17 1998-04-21 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5576321A (en) 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
WO1996024353A1 (en) 1995-02-10 1996-08-15 Eli Lilly And Company Methods of treating or preventing psychiatric disorders
CR5278A (es) 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
EG23659A (en) 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
CA2218143A1 (en) 1995-04-18 1996-10-24 Eli Lilly And Company Method for using ergoline compounds to effect physiological and pathological functions at the 5-ht7 receptor
US5889010A (en) 1995-05-18 1999-03-30 Pfizer Inc. Benzimidazole derivatives having dopaminergic activity
US20010023248A1 (en) 1995-05-25 2001-09-20 Howard Harry R. Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
MX9800187A (es) 1995-07-07 1998-05-31 Pfizer Compuestos de benzolactama substituidos como antagonistas de la substancia p.
KR19990035817A (ko) 1995-07-24 1999-05-25 피터 지. 스트링거 주의력 결핍증/활동항진증의 치료 방법
US5696168A (en) 1995-07-24 1997-12-09 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
TW340842B (en) 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
IL115113A (en) 1995-08-31 2002-11-10 Israel State 3-carbamoyloxy pyridinium derivatives and pharmaceutical compositions containing them
ES2100129B1 (es) 1995-10-11 1998-02-16 Medichem Sa Nuevos compuestos aminopiridinicos policiclicos inhibidores de acetilcolinesterasa, procedimiento para su preparacion y su utilizacion.
EP0874818B1 (en) 1995-11-17 2003-05-21 MERCK &amp; CO. INC. Novel substituted aryl compounds useful as modulators of acetylcholine receptors
US5783584A (en) 1995-12-11 1998-07-21 Mayo Foundation For Medical Education And Research THA analogs useful as cholinesterase inhibitors
DK0780375T3 (da) 1995-12-21 2002-10-07 Pfizer 3-((5-substitueret benzyl)amino)-2-phenylpiperidiner som substans P-antagonister
KR19990076689A (ko) 1995-12-22 1999-10-15 피터 지. 스트링거 우울증 치료 방법
US5625897A (en) 1996-01-11 1997-05-06 Park; Kelly R. Upper torso garment
WO1997026300A1 (en) 1996-01-22 1997-07-24 Eli Lilly And Company Combinatorial process for preparing substituted indane libraries
GB9606736D0 (en) 1996-02-19 1996-06-05 Shire International Licensing Therapeutic method
EA000758B1 (ru) 1996-03-11 2000-04-24 Эли Лилли Энд Компани Способ лечения биполярного расстройства
EP0906104A4 (en) 1996-03-25 2003-12-10 Lilly Co Eli PAIN TREATMENT PROCESS
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
US6326368B1 (en) 1996-03-27 2001-12-04 Dupont Pharmaceuticals Company Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof
SK113998A3 (en) 1996-03-29 2001-05-10 Pfizer 6-phenylpyridyl-2-amine derivatives
DE69733996T2 (de) 1996-03-29 2006-07-20 Pfizer Inc. Benkyl(idene)-lactam-derivate, deren herstellung und verwendung als selektive (ant)agonisten von 5-ht1a- und/oder 5-ht1d rezeptoren
ATE207483T1 (de) 1996-04-12 2001-11-15 Aventis Pharma Inc Isatinderivate als acetylcholinesterase- inhibitoren und analgetika
JP3102896B2 (ja) 1996-05-07 2000-10-23 ファイザー インク． ５―（２―（４―（１，２―ベンズイソチアゾール―３―イル）―１―ピペラジニル）エチル）―６―クロロ―１，３―ジヒドロ―２（１ｈ）―インドール―２―オン（＝ジプラシドン）のメシレート三水和物、その調製法およびドーパミンｄ２アンタゴニストとしてのその使用
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
ZA973884B (en) 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
US5948437A (en) 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
EP1380298A3 (en) 1996-05-23 2004-04-07 Bristol-Myers Squibb Pharma Company Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders, anorexia, inflammation
PT810220E (pt) 1996-05-28 2002-04-29 Pfizer Derivados de arilacrilamida como agonistas ou antigonistas de 5ht1
WO1997046526A1 (en) 1996-06-07 1997-12-11 Eisai Co., Ltd. Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production
TW513409B (en) 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
US6329396B1 (en) 1996-06-10 2001-12-11 Pfizer Inc. Substituted benzylaminopiperidine compounds
US5912256A (en) 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
CA2180703A1 (en) 1996-07-08 1998-01-09 Paul Marie Victor Gilis Fast-dissolving galanthamine hydrobromide tablet
US7094782B1 (en) 1996-07-24 2006-08-22 Bristol-Myers Squibb Company Azolo triazines and pyrimidines
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
DK0915880T3 (da) 1996-07-24 2008-02-11 Bristol Myers Squibb Pharma Co Azolotriaziner og pyrimidiner
US6117890A (en) 1996-08-01 2000-09-12 Eli Lilly And Company Method for treating bipolar disorder
US6043258A (en) 1996-08-01 2000-03-28 Eli Lilly And Company Method for treating disruptive behavior disorders with xanomeline
DK0821955T3 (da) 1996-08-01 2002-03-18 Lilly Co Eli Anvendelse af 3-(4-heoxyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridin (xanomelin) til behandling af bipolar lidelse
MX9706196A (es) 1996-08-14 1998-02-28 Pfizer Compuestos triciclicos de piperidinilamino como antagonistas de la sustancia p.
WO1998007431A1 (en) 1996-08-22 1998-02-26 New York University Cholinesterase inhibitors for treatment of parkinson's disease
BR9711541A (pt) 1996-09-23 1999-08-24 Lilly Co Eli Dihidrato d de olanzapina
ZA977967B (en) 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US6423708B1 (en) 1996-09-30 2002-07-23 Pfizer Inc Aralkyl and aralkylidene heterocyclic lactams and imides
UA56185C2 (uk) 1996-09-30 2003-05-15 Пфайзер Інк. Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
IT1285801B1 (it) 1996-10-10 1998-06-24 Sigma Tau Ind Farmaceuti Procedimento migliorato per la preparazione dell'acido valproico
WO1998018798A1 (en) 1996-10-30 1998-05-07 Pfizer Inc. Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy
AU5716898A (en) 1997-01-08 1998-08-03 Warner-Lambert Company Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
PT964849E (pt) 1997-01-29 2003-08-29 Pfizer Derivados de sulfonilureia e sua utilizacao no controlo da actovidade da interleucina-1
US6020335A (en) 1997-02-06 2000-02-01 Pfizer Inc (N-(pyridinylmethyl)-heterocyclic)ylideneamine compounds as nicotinic acetylcholine receptor binding agents
JP4095676B2 (ja) 1997-03-03 2008-06-04 エーザイ株式会社 注意障害を治療するためのコリンエステラーゼ阻害剤の使用
GB2323788B (en) 1997-04-02 1999-02-17 Bristol Myers Squibb Co Venting valve for ostomy bag
CN1254335A (zh) 1997-04-04 2000-05-24 辉瑞产品公司 烟酰胺衍生物
ZA982877B (en) 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
WO1998046226A1 (en) 1997-04-11 1998-10-22 Eli Lilly And Company Method for treating schizophrenia
AU6896098A (en) 1997-04-11 1998-11-11 Eli Lilly And Company Method for treating schizophrenia
US5910319A (en) 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
US6627755B1 (en) 1997-06-09 2003-09-30 Pfizer Inc Quinazolin-4-one AMPA antagonists
DE69831446T2 (de) 1997-06-09 2006-06-14 Pfizer Prod Inc Chinazolin-4-on AMPA Antagonisten
US6060479A (en) 1997-06-09 2000-05-09 Pfizer Inc Quinazoline-4-one AMPA antagonists
WO1999004778A1 (en) 1997-07-22 1999-02-04 Eli Lilly And Company Pharmaceutical compounds
GB9716879D0 (en) 1997-08-08 1997-10-15 Shire Int Licensing Bv Treatment of attention deficit disorders
WO1999008672A1 (en) 1997-08-15 1999-02-25 Shire International Licensing Bv Use of cholinesterase inhibitor for treating diseases associated with proteolytic enzyme activity
US6479523B1 (en) 1997-08-26 2002-11-12 Emory University Pharmacologic drug combination in vagal-induced asystole
IL125951A (en) 1997-09-05 2003-09-17 Pfizer Prod Inc A pharmaceutical composition comprising a piperazinyl-heterocyclic compound for treating tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal
US6323208B1 (en) 1997-09-05 2001-11-27 Pfizer Inc Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones
CA2304112A1 (en) 1997-09-23 1999-04-01 John Harrison Heiligenstein Treatment of attention-deficit/hyperactivity disorder
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
ES2218869T3 (es) 1997-12-05 2004-11-16 Eisai Co., Ltd. Cristales polimorficos de donepezil y un proceso para produccion de dichos cristales.
EP1045834A1 (en) 1997-12-16 2000-10-25 Warner-Lambert Company 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
IL127497A (en) 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
SI1049699T1 (en) 1998-01-28 2004-10-31 Bristol-Myers Squibb Pharma Company Pyrazolotriazines as crf antagonists
US6131106A (en) 1998-01-30 2000-10-10 Sun Microsystems Inc System and method for floating-point computation for numbers in delimited floating point representation
WO1999039725A1 (en) 1998-02-06 1999-08-12 Eli Lilly And Company Desert hedgehog related nucleic acids and proteins
GB9805561D0 (en) 1998-03-16 1998-05-13 Merck Sharp & Dohme A combination of therapeutic agents
PA8469101A1 (es) 1998-04-09 2000-09-29 Pfizer Prod Inc Ligandos azabiciclicos de receptores 5ht1
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
ATE228119T1 (de) 1998-04-15 2002-12-15 Pfizer Prod Inc Heterocyclische carboxamide
EP0952154B1 (en) 1998-04-16 2004-08-18 Pfizer Products Inc. N-acyl and N-aroyl aralkyl amides
AU3891299A (en) 1998-05-21 1999-12-06 Eli Lilly And Company Combination therapy for treatment of depression
US6960577B2 (en) 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
GT199900060A (es) 1998-05-22 2000-10-14 Polimorfos de un monoclorhidrato de pirazina cristalino y sus composiciones farmacèuticas.
EP0958824A3 (en) 1998-05-22 1999-12-01 Eli Lilly And Company Olanzapine (zyprexa) in combination with fluoxetine (prozac), lithium or anticonvulsant for therapy of refractory depression
CA2332408A1 (en) 1998-05-29 1999-12-09 Eli Lilly And Company Combination therapy for treatment of bipolar disorders
US6150366A (en) 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
US6436914B1 (en) 1998-06-30 2002-08-20 Bristol-Myers Squibb Company 2-hydroxy-3—(4-hydroxy-3-sulfonamidophenyl)—propylamines useful as beta 3 adrenergic agonists
US6312717B1 (en) 1998-07-07 2001-11-06 Bristol-Myers Squibb Company Method for treatment of anxiety and depression
US6262081B1 (en) 1998-07-10 2001-07-17 Dupont Pharmaceuticals Company Composition for and method of treating neurological disorders
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
KR20010072368A (ko) 1998-08-11 2001-07-31 실버스타인 아써 에이. 포스포디에스테라제 4 억제제로서의 치환된1,8-나프티리딘-4(1수소)-온
IL125809A (en) 1998-08-17 2005-08-31 Finetech Lab Ltd Process and intermediates for production of donepezil and related compounds
IT1304904B1 (it) 1998-09-11 2001-04-05 Eisai Co Ltd Derivati anticolinesterasici per il trattamento delle sindromidolorose funzionali e/o organiche
HN1999000146A (es) 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
PL348107A1 (en) 1998-10-16 2002-05-06 Janssen Pharmaceutica Nv Therapy for improving cognition
US5994352A (en) 1998-11-13 1999-11-30 Pfizer Inc. 5-arylindole derivatives
CA2351347A1 (en) 1998-11-23 2000-06-02 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
AU1602100A (en) 1998-11-25 2000-06-13 Warner-Lambert Company Improved gamma amino butyric acid analogs
ATE306264T1 (de) 1998-12-11 2005-10-15 Bonnie M Davis Verwendung von acetylcholinesterase inhibitoren zur modulierung der hypothalamus-hypophysen- gonadenachse
UA62015C2 (en) 1998-12-28 2003-12-15 Pfizer Prod Inc Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants)
US6271380B1 (en) 1998-12-30 2001-08-07 Dupont Pharmaceuticals Company 1H-imidazo[4,5-d]pyridazin-7-ones, 3H-imidazo-[4,5-c]pyridin-4-ones and corresponding thiones as corticotropin releasing factor (CRF) receptor ligands
AU2180400A (en) 1999-01-13 2000-08-01 Eli Lilly And Company A pharmaceutical combination for the treatment of depression
CA2363145C (en) 1999-03-01 2006-02-14 Pfizer Products Inc. Oxamic acids and derivatives as thyroid receptor ligands
EP1033364B1 (en) 1999-03-01 2005-02-23 Pfizer Products Inc. Cyano containing oxamic acids and derivatives as thyroid receptor ligands
US6277866B1 (en) 1999-03-03 2001-08-21 Eisai Co., Ltd. 1-benzyl-4[(5,6-dimethoxy-2-fluoro-1-indanon)-2-yl]methylpiperidine
EP1086706B1 (en) 1999-03-31 2003-11-26 Eisai Co., Ltd. Stabilized compositions containing nootropic drugs
EP1050303A3 (en) 1999-04-27 2003-01-15 Pfizer Products Inc. Methods and compositions for treating age-related behavioral disorders in companion animals
EE200100611A (et) 1999-05-21 2003-02-17 Pfizer Products Inc. NOS inhibiitorite uued farmatseutilised kombinatsioonid
AU4973800A (en) 1999-06-09 2000-12-28 Eli Lilly And Company Combination for treating weight gain associated with antipsychotic use comprising an atypical antipsychotic and an h2 antagonist
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
IL147108A0 (en) 1999-06-15 2002-08-14 Du Pont Pharm Co Substituted heterocycle fused gamma-carbolines
AU6053900A (en) 1999-06-25 2001-01-31 Morris Notelovitz Compositions for treating or preventing neurodegeneration and cognitive decline
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
JP4242048B2 (ja) 1999-09-01 2009-03-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 ４−置換ピペリジン誘導体
DE60034577T2 (de) 1999-09-01 2007-12-27 Eisai R&D Management Co., Ltd. In 4-stellung substituierte piperidinderivate
ATE264301T1 (de) 1999-09-22 2004-04-15 Schering Corp Muscarin-antagonisten
EP1088819B1 (en) 1999-09-30 2005-06-15 Pfizer Products Inc. 6-azauracil derivatives as thyroid receptor ligands
CA2324813A1 (en) 1999-11-10 2001-05-10 Susan Beth Sobolov-Jaynes Combination treatment for depression and anxiety
US6620802B1 (en) 1999-11-23 2003-09-16 Corcept Therapeutics, Inc. Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist
YU37602A (sh) * 1999-12-01 2005-07-19 Ucb S.A. Derivat pirolidinacetamida sam ili u kombinaciji za tretman poremećaja cns
JP2003516992A (ja) 1999-12-17 2003-05-20 デュポン ファーマシューティカルズ カンパニー イミダゾピリミジニル誘導体およびイミダゾピリジニル誘導体
WO2001043740A1 (en) 1999-12-17 2001-06-21 Bristol-Myers Squibb Company Antipsychotic heterocycle compounds
EP1242411B1 (en) 1999-12-20 2006-03-08 Eli Lilly And Company Indole derivatives for the treatment of depression and anxiety
AU1930901A (en) 1999-12-20 2001-07-03 Eli Lilly And Company Azabicyclo(3.2.1)octane derivatives
AU2049501A (en) 1999-12-20 2001-07-03 Eli Lilly And Company Benzofuran derivatives
US6844344B2 (en) 1999-12-20 2005-01-18 Eli Lilly And Company Benzofuran derivatives
DE60010758T2 (de) 1999-12-20 2005-05-12 Eli Lilly And Co., Indianapolis Piperidin-derivate und ihre verwendung als serotonin rezeptor antagonisten
ES2225031T3 (es) 1999-12-29 2005-03-16 Pfizer Products Inc. Compuestos de 3-((2-piperazinil-fenil)metil)-1-(4-(trifluorometil)fenil)-2-pirrolidinona opticamente activos como antagonistas selectivos del receptor de 5-ht1d.
EP1127882A1 (en) 2000-01-25 2001-08-29 Pfizer Products Inc. Tetrazole compounds as thyroid receptor ligands
NZ520023A (en) 2000-02-17 2004-05-28 Bristol Myers Squibb Co Aniline-derived ligands for the thyroid receptor
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
DK1311272T3 (da) 2000-03-03 2007-02-26 Eisai R&D Man Co Ltd Hidtil ukendte fremgangsmåder hvor der anvendes cholinesteraseinhibitorer
US20030144255A1 (en) 2000-03-06 2003-07-31 Bain Allen I Compositions for prevention and treatment of dementia
EP1265857A1 (en) 2000-03-13 2002-12-18 Eli Lilly And Company Sulfonamide derivatives
US6664291B2 (en) 2000-03-31 2003-12-16 Pfizer, Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands
GB0007884D0 (en) 2000-03-31 2000-05-17 Pfizer Ltd Diphenyl ether compounds useful in therapy
WO2001072692A1 (en) 2000-03-31 2001-10-04 Pfizer Products Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands
AU6383101A (en) 2000-04-08 2001-10-23 Boehringer Ingelheim Pharma Kg Bicyclic heterocylces, medicaments containing said compounds, the use thereof and method for producing them
YU73902A (sh) 2000-04-10 2005-09-19 Pfizer Products Inc. Jedinjenja koja sadrže benzoamid-piperidin i srodna jedinjenja
WO2001078728A1 (fr) 2000-04-13 2001-10-25 Eisai Co., Ltd. Inhibiteurs d'acetylcholinesterases contenant des sels de 1-benzyl-pyridinium
US6620830B2 (en) 2000-04-21 2003-09-16 Pfizer, Inc. Thyroid receptor ligands
US20010036949A1 (en) 2000-05-09 2001-11-01 Coe Jotham Wadsworth Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal
US6630469B2 (en) 2000-05-09 2003-10-07 Bristol-Myers Squibb Company 5-HT7 receptor antagonists
US20040229911A1 (en) 2000-05-17 2004-11-18 Pfizer Inc New pharmaceutical combinations for NOS inhibitors
CA2410531A1 (en) 2000-05-24 2001-11-29 Eli Lilly And Company Combination therapy for treatment of depression
EP1290167A1 (en) 2000-05-26 2003-03-12 Bristol-Myers Squibb Company Human kcnq5 potassium channel, methods and compositions thereof
AU2001258690A1 (en) 2000-06-02 2001-12-11 Pfizer Products Inc. S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders
US6395784B1 (en) 2000-06-07 2002-05-28 Bristol-Myers Squibb Company Benzamide ligands for the thyroid receptor
DOP2001000189A (es) 2000-06-30 2002-03-30 Pfizer Prod Inc Benzofenonas y sulfonas como inhibidores de la captación de glicina
AU2001268055A1 (en) 2000-06-30 2002-01-14 Eli Lilly And Company Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist
US6630476B2 (en) 2000-07-07 2003-10-07 Bristol-Myers Squibb Pharma Company Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists
EP1177792A3 (en) 2000-07-27 2002-10-23 Pfizer Products Inc. Dopamine D4 Ligands for the treatment of novelty-seeking disorders
US6756385B2 (en) 2000-07-31 2004-06-29 Pfizer Inc. Imidazole derivatives
US20020016334A1 (en) 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
US20020049211A1 (en) 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
WO2002019998A2 (en) 2000-09-08 2002-03-14 Eli Lilly And Company A method of treating weight gain associated with atypical antipsychotic use
US6515005B2 (en) 2000-09-21 2003-02-04 Bristol-Myers Squibb Company Substituted azole derivatives as inhibitors of corticotropin releasing factor
EP1192952A3 (en) 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
IL145584A0 (en) 2000-10-02 2002-06-30 Pfizer Prod Inc Nmda nr2b antagonists for treatment
US20020151591A1 (en) 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders
US20020103198A1 (en) 2000-12-04 2002-08-01 Fliri Anton F.J Acylamino cyclopropane derivatives
CA2364211A1 (en) 2000-12-05 2002-06-05 Phillip Branch Chappell Combination treatment for depression, anxiety and psychosis
UA73619C2 (en) 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
IL156354A0 (en) 2000-12-20 2004-01-04 Bristol Myers Squibb Co Pyridoindole derivatives and pharmaceutical compositions containing the same
ATE318819T1 (de) 2000-12-20 2006-03-15 Bristol Myers Squibb Pharma Co Pyrazinochinoxalin-derivate als serotonin- agonisten und -antagonisten
IL156261A0 (en) 2000-12-20 2004-01-04 Bristol Myers Squibb Co Pyrroloquinoline and pyridoquinoline derivatives and pharmaceutical compositions containing the same
US6849619B2 (en) 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
US7608636B2 (en) 2000-12-28 2009-10-27 Hamilton Pharmaceuticals, Inc. Medicines for treatment and prevention of neurogenic pain
US20020086871A1 (en) 2000-12-29 2002-07-04 O'neill Brian Thomas Pharmaceutical composition for the treatment of CNS and other disorders
US6436938B1 (en) 2001-01-22 2002-08-20 Pfizer Inc. Combination treatment for depression
RU2003126188A (ru) 2001-01-26 2005-03-27 Бристол-Маерс Сквибб Компани (Us) Имидазолильные производные как ингибиторы кортикотропин-рилизинг фактора
US20020107244A1 (en) 2001-02-02 2002-08-08 Howard Harry R. Combination treatment for depression
US6610326B2 (en) 2001-02-16 2003-08-26 Andrx Corporation Divalproex sodium tablets
JP2004523557A (ja) 2001-02-23 2004-08-05 ジョンズ・ホプキンス・ユニバーシティ チック、振せん、および関連疾患の治療
US20020123490A1 (en) 2001-03-01 2002-09-05 Pfizer Inc. Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
WO2002072101A1 (en) 2001-03-13 2002-09-19 Bristol-Myers Squibb Pharma Company A corticotropin releasing factor receptor ligand, its enantiomer and pharmaceutically acceptable salts
CA2440553C (en) 2001-03-13 2010-06-08 Paul J. Gilligan 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands
EP1372620A2 (en) 2001-03-15 2004-01-02 Saegis Pharmaceuticals Methods for restoring cognitive function following systemic stress
JP2004531506A (ja) 2001-03-29 2004-10-14 ブリストル−マイヤーズ　スクイブ　カンパニー 選択的なセロトニン再取り込みインヒビターとしてのシクロプロピルインドール誘導体
CN1610547A (zh) 2001-03-29 2005-04-27 伊莱利利公司 用作5－ht6受体拮抗剂的n－(2－芳乙基)苄胺
YU78803A (sh) 2001-04-19 2006-08-17 Warner-Lambert Company Fuzija bicikličnih ili tricikličnih amino kiselina
US20030018047A1 (en) 2001-04-20 2003-01-23 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
IL149106A0 (en) 2001-04-20 2002-11-10 Pfizer Prod Inc Therapeutic use of selective pde10 inhibitors
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
EP1666886A3 (en) 2001-04-20 2006-06-21 Pfizer Products Inc. Method of identifying selective PDE10 inhibitor compounds
MY129350A (en) 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
AU2756602A (en) 2001-04-25 2002-10-31 Pfizer Products Inc. Methods and kits for treating depression or preventing deterioration of cognitive function
US20020165217A1 (en) 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
ATE315555T1 (de) 2001-05-11 2006-02-15 Pfizer Prod Inc Thiazolderivate und ihre verwendung als cdk- inhibitoren
EE200300546A (et) 2001-05-14 2004-04-15 Bristol-Myers Squibb Pharma Company Asendatud pürasinoonid, püridiinid ja pürimidiinid kui kortikotropiini vabastava faktori ligandid
WO2002094787A1 (en) 2001-05-23 2002-11-28 Ucb, S.A. 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders
EP1260221A3 (en) 2001-05-23 2002-12-18 Pfizer Products Inc. Combination treatment for depression and anxiety
US6566550B2 (en) 2001-06-21 2003-05-20 Pfizer Inc Substituted aromatic ethers as inhibitors of glycine transport
US20030008892A1 (en) 2001-07-09 2003-01-09 Pfizer Inc. Pharmaceutical composition and method of modulating cholinergic function in a mammal
US6894045B2 (en) 2001-07-12 2005-05-17 Bristol-Myers Squibb Pharma Company Tetrahydropurinones and derivatives thereof as corticotropin releasing factor receptor ligands
WO2003006015A1 (en) 2001-07-13 2003-01-23 Bristol-Myers Squibb Pharma Company Substituted thiazoles and oxazoles as corticotropin releasing hormone ligands
US6821976B2 (en) 2001-07-24 2004-11-23 Bristol-Myers Squibb Company S-6-hydroxy-buspirone
EP1408979A4 (en) 2001-07-24 2005-03-23 Bristol Myers Squibb Co R-6-HYDROXY-BUSPIRONE
US8354438B2 (en) 2001-08-08 2013-01-15 Michael Chez Neurological functions
ES2248493T3 (es) 2001-08-16 2006-03-16 Pfizer Products Inc. Difluorometilen-eteres aromaticos y su uso como inhibidores del transportador de glicina tipo 1.
JP2005501108A (ja) 2001-08-22 2005-01-13 第一製薬株式会社 神経変性治療におけるネフィラセタムの使用
US20030060423A1 (en) 2001-08-30 2003-03-27 Plata-Salaman Carlos R. Co-therapy for the treatment of dementia and associated behavioral manifestations comprising anticonvulsant derivatives and acetylcholinesterase inhibitors
WO2003022820A1 (en) 2001-09-06 2003-03-20 Bristol-Myers Squibb Pharma Company. Heteroaromatic substituted cyclopropane as corticotropin releasing hormone
EP1297833B1 (en) 2001-09-26 2005-12-21 Pfizer Products Inc. Indole carboxylic acids as thyroid receptor ligands
US20040235957A1 (en) 2001-10-12 2004-11-25 David Bleakman Use of sulfonamide derivatives as pharmaceuticals compounds
DE60233884D1 (de) 2001-10-16 2009-11-12 Memory Pharmaceutical Corp 4(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidon-derivate als pde-4-hemmer zur behandlung von neurologischen syndromen
KR20010113584A (ko) 2001-11-08 2001-12-28 (주)시스튜디오 컴퓨터에 의한 만화 애니메이션 구현방법 및 만화애니메이션 실행데이터를 기록한 컴퓨터로 읽을 수 있는기록매체
US6673811B1 (en) 2001-11-19 2004-01-06 Neurogen Corporation 1H-pyrrolo [3,2-b] pyridine-3-carboxylic acid amines as GABAA receptor ligands
AU2002340405A1 (en) 2001-11-20 2003-06-10 Bristol-Myers Squibb Pharma Company 3,7-dihydro-purine-2,6-dione derivatives as crf receptor ligands
US6992087B2 (en) 2001-11-21 2006-01-31 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
MXPA02010430A (es) 2001-11-27 2003-06-02 Warner Lambert Co Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.
US20050009925A1 (en) 2001-12-11 2005-01-13 Bymaster Franklin Porter Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure
US6495700B1 (en) 2002-01-09 2002-12-17 Axonyx, Inc. Process for producing phenserine and its analog
US20050009927A1 (en) 2002-01-23 2005-01-13 Pfizer Inc Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors
US20050014848A1 (en) 2002-01-23 2005-01-20 Pfizer Inc. Combination of serotonin reuptake inhibitors and norephinephrine reuptake inhibitors
JP2005532268A (ja) 2002-02-22 2005-10-27 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 置換されたピリミジノンおよびピリミジンチオン
US20040167200A1 (en) 2002-03-25 2004-08-26 Pfizer Inc. Pharmaceutical composition and method of modulating cholinergic function in a mammal
GB0207104D0 (en) 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
JP2005533009A (ja) 2002-03-28 2005-11-04 イーライ・リリー・アンド・カンパニー ピペラジン置換されたアリールベンゾジアゼピン類およびそのドーパミン受容体アンタゴニストとしての精神病性障害の処置のための使用
US6759552B2 (en) 2002-03-28 2004-07-06 Council Of Scientific And Industrial Research Compound as cholinesterase inhibitor and its isolation from fungus sporotrichum species
DE60318306T2 (de) 2002-03-29 2008-12-11 Eisai R&D Management Co., Ltd. (1-indanon)-(1,2,3,6-tetrahydropyridin)derivat
WO2003084610A1 (en) 2002-04-03 2003-10-16 Eli Lilly And Company Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist
US6713490B2 (en) 2002-04-26 2004-03-30 Pfizer, Inc. 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
ATE413388T1 (de) 2002-04-26 2008-11-15 Schering Corp Muskarin antagonisten
WO2004034963A2 (en) 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
PT1509232E (pt) 2002-05-31 2009-01-07 Lundbeck & Co As H Uma combinação de um antagonista de nmda e inibidores da acetilcolina esterase para o tratamento da doença de alzheimer
US6710040B1 (en) 2002-06-04 2004-03-23 Pfizer Inc. Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
US20040001895A1 (en) 2002-06-17 2004-01-01 Pfizer Inc. Combination treatment for depression and anxiety
US20030235631A1 (en) 2002-06-17 2003-12-25 Pfizer Inc. Combination treatment for depression and anxiety
US20040006135A1 (en) 2002-06-19 2004-01-08 Pfizer Inc. Combination treatment for depression and anxiety
US20040116506A1 (en) 2002-06-20 2004-06-17 Krusz John Claude Use of levetiracetam for treating or preventing acute headaches
US6875771B2 (en) 2002-07-26 2005-04-05 Bristol-Myers Squibb Company Pyridopyrimidine derivatives as 5-HT6 antagonists
US7557137B2 (en) 2002-08-05 2009-07-07 Bristol-Myers Squibb Company Gamma-lactams as beta-secretase inhibitors
ES2285227T3 (es) 2002-08-05 2007-11-16 Eli Lilly And Company Arilbenzodiazepinas sustituidas con piperazina.
US7053122B2 (en) 2002-08-09 2006-05-30 Pfizer Inc Therapeutic use of aryl amino acid derivatives
GB0219154D0 (en) 2002-08-16 2002-09-25 Pfizer Ltd Diaryl compounds
GB0219153D0 (en) 2002-08-16 2002-09-25 Pfizer Ltd Substituted glycine derivatives for use as medicaments
SI1542668T1 (sl) 2002-08-20 2009-08-31 Bristol Myers Squibb Co Aripiprazol sestavljena formulacija in postopek
EP1551843A1 (en) 2002-09-10 2005-07-13 Pfizer Products Inc. Diazabicyclic compounds useful in the treatment of cns and other disorders
WO2004026236A2 (en) 2002-09-18 2004-04-01 Bristol-Myers Squibb Company Cyclopentyl indole derivatives
TW200418838A (en) 2002-09-18 2004-10-01 Bristol Myers Squibb Co Compounds for the treatment of premature ejaculation
US7635709B2 (en) 2002-09-26 2009-12-22 The United States Of America As Represented By The Department Of Veterans Affairs Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction
US7067658B2 (en) 2002-09-30 2006-06-27 Bristol-Myers Squibb Company Pyridino and pyrimidino pyrazinones
GB0223494D0 (en) 2002-10-09 2002-11-13 Neuropharma Sa Dual binding site acetylcholinesterase inhibitors for the treatment of alzheimer's disease
UA83645C2 (ru) 2002-10-24 2008-08-11 Мерц Фарма Гмбх Унд Ко. Кгаа Фармацевтический продукт, который содержит производное 1-аминоциклогексана и ингибитор ацетилхолинестеразы, его применение
NZ566615A (en) 2002-10-24 2009-08-28 Pfizer Prod Inc Acyl derivatives of 5-(2-(4-(1,2 benzisothiazole-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one having neuroleptic activity
GB0225379D0 (en) 2002-10-31 2002-12-11 Pfizer Ltd Therapeutic proline derivatives
JP2006508975A (ja) 2002-11-18 2006-03-16 ファイザー・プロダクツ・インク ジペプチジルペプチダーゼｉｖを阻害するフッ素化環状アミド
WO2004047743A2 (en) 2002-11-22 2004-06-10 Bristol-Myers Squibb Company 1-aryl-2-hydroxyethyl amides as potassium channel openers
AU2003302472B2 (en) 2002-11-22 2010-10-21 The Johns Hopkins University Target for therapy of cognitive impairment
US6900210B2 (en) 2002-11-22 2005-05-31 Bristol-Myers Squibb Company Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers
AU2003294443A1 (en) 2002-11-22 2004-06-18 Bristol-Myers Squibb Company 3-(pyridinyl-piperazin-1-yl)-phenylethyl amides as potassium channel openers
AU2003294442A1 (en) 2002-11-22 2004-06-18 Bristol-Myers Squibb Company 3-heterocyclic benzylamide derivatives as potassium channel openers
AU2003295781A1 (en) 2002-11-22 2004-06-18 Bristol-Myers Squibb Company Arylcyclopropylcarboxylic amides as potassium channel openers
US7090985B2 (en) 2002-12-03 2006-08-15 Ucb, S.A. Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
US7465549B2 (en) 2002-12-03 2008-12-16 Ucb, S.A. Methods for identifying agents that bind a levetiracetam binding site (LBS) or compete with LEV binding to a LBS of a synaptic vesicle protein 2 (SV2)
CA2509142A1 (en) 2002-12-11 2004-06-24 Pharmacia & Upjohn Company Llc Combination for the treatment of adhd
WO2004052348A2 (en) 2002-12-11 2004-06-24 Pharmacia & Upjohn Company Llc Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds
EP1592772A2 (en) 2003-01-31 2005-11-09 Pfizer Products Incorporated 5ht7 antagonists and inverse agonists
BRPI0408113A (pt) 2003-03-06 2006-03-01 Celgene Corp métodos para tratar ou prevenir um distúrbio do sistema nervoso central, para controlar um distúrbio do sistema nervoso central e para reduzir ou evitar um efeito adverso associado com a administração de um ingrediente ativo secundário em um paciente que sofre de um distúrbio do sistema nervoso central, e, composição farmacêutica
EP1608648B1 (en) 2003-03-12 2012-07-18 Pfizer Products Inc. Pyridyloxymethyl and benzisoxazole azabicyclic derivatives
ITMI20030573A1 (it) 2003-03-24 2004-09-25 Nikem Research Srl Composti ad azione nootropica, loro preparazione,
US20040191334A1 (en) 2003-03-24 2004-09-30 Pang-Chui Shaw Use of transhinone derivates as cholinesterase inhibitors in treating related diseases
JP2006521343A (ja) 2003-03-27 2006-09-21 ファイザー・プロダクツ・インク 置換４−アミノ［１，２，４］トリアゾロ［４，３−ａ］キノキサリン
TW200508197A (en) 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
US7041671B2 (en) 2003-04-02 2006-05-09 Pfizer Inc Pyrrolo[1,2-b]pyridazine compounds and their uses
US7034023B2 (en) 2003-04-04 2006-04-25 Pfizer Inc Pyrrolo[1,2-B]pyridazine compounds and their uses
US7056920B2 (en) 2003-04-04 2006-06-06 Pfizer Inc Pyrrolo[1,2-B]pyridazine compounds and their uses
CA2522323C (en) 2003-04-14 2009-09-15 Pfizer Products Inc. 3-azabicyclo[3.2.1]octane derivatives as opioid receptor ligands
US7056930B2 (en) 2003-04-14 2006-06-06 Pfizer Inc. 2-Azabicyclo[3.3.1]nonane derivatives
US20040204453A1 (en) 2003-04-14 2004-10-14 Pfizer Inc 4-Phenyl-piperidine compounds and their use as modulators of opioid receptors
US7030145B2 (en) 2003-04-18 2006-04-18 Bristol-Myers Squibb Company Pyridinyl derivatives for the treatment of depression
US7112585B2 (en) 2003-04-18 2006-09-26 Bristol-Myers Squibb Company Pyrimidine derivatives as corticotropin releasing factor inhibitors
MXPA05011387A (es) 2003-04-23 2005-12-01 Pharmacia & Upjohn Co Llc Pirimidinonas y pirimidinotionas sustituidas.
GB0309440D0 (en) 2003-04-25 2003-06-04 Lilly Co Eli Quinolone derivatives
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
JP2006525309A (ja) 2003-05-07 2006-11-09 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー ピロロ（１，２−ｂ）ピリダジン化合物、ならびにＣＲＦ−１受容体拮抗薬としてのその使用
EP1625115A1 (en) 2003-05-09 2006-02-15 Pharmacia & Upjohn Company LLC Substituted pyrimidine derivatives
BRPI0410378A (pt) 2003-05-16 2006-06-13 Pfizer Prod Inc tratamento de distúrbios psicóticos e depressivos
AU2004237961A1 (en) 2003-05-16 2004-11-25 Pfizer Products Inc. Treatment of bipolar disorders and associated symptoms
CA2525323A1 (en) 2003-05-16 2004-11-25 Pfizer Products Inc. Method for enhancing cognition using ziprasidone
AU2004237951A1 (en) 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with GABA modulators, anticonvulsants or benzodiazapines
DK1626721T3 (en) 2003-05-23 2017-01-23 Otsuka Pharma Co Ltd CARBOSTYRIL DERIVATIVES AND Mood Stabilizers for the Treatment of Mood Disorders
US7101881B2 (en) 2003-06-11 2006-09-05 Pfizer Inc Tetrahydroquinolines
EP1638932A1 (en) 2003-06-18 2006-03-29 Pfizer Products Inc. Novel piperazinyl-aryloxy and piperazinyl-heteroaryloxy-n-aryl lactams
CA2525245C (en) 2003-06-27 2010-10-19 Pfizer Products Inc. Pyrazolo[3,4-b]pyridin-6-ones as gsk-3 inhibitors
EP1641454B1 (en) 2003-06-27 2008-10-01 Pfizer Products Inc. Pyrazolo[3,4-b]pyridin-6-ones as gsk-3 inhibitors
US20050070577A1 (en) 2003-07-03 2005-03-31 Pfizer Inc. Compositions containing a serotonin selective reuptake inhibitor and a 5-HT2A receptor antagonist
WO2005013961A1 (en) 2003-07-17 2005-02-17 Eli Lilly And Company Combination therapy for treatment of cognitive disorders or psychoses
TW200510324A (en) 2003-08-11 2005-03-16 Lilly Co Eli 6-(2,2,2-trifluoroethylamino)-7-chiloro-2, 3, 4, 5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist
WO2005019168A2 (en) 2003-08-20 2005-03-03 Pfizer Products Inc. Fluorinated lysine derivatives as dipeptidyl peptidase iv inhibitors
WO2005026177A1 (en) 2003-09-09 2005-03-24 Eli Lilly And Company Substituted piperazines of azepines, oxazepines, and thiazepines
MXPA06002778A (es) 2003-09-09 2006-06-14 Pfizer Prod Inc Combinacion de inhibidores de recaptacion de serotonina e inhibidores de recaptacion de norepinefrina.
GB0322140D0 (en) 2003-09-22 2003-10-22 Pfizer Ltd Combinations
US7244843B2 (en) 2003-10-07 2007-07-17 Bristol-Myers Squibb Company Modulators of serotonin receptors
BRPI0415113A (pt) 2003-10-08 2006-11-28 Pfizer compostos de lactama condensados
ATE430729T1 (de) 2003-10-08 2009-05-15 Lilly Co Eli Pyrrol- und pyrazolderivate als potentiatoren von glutamatrezeptoren
US20050080100A1 (en) 2003-10-09 2005-04-14 Pfizer Inc Pyridylamino compounds and methods of use thereof
RU2006112576A (ru) 2003-10-16 2006-08-27 Пфайзер Продактс Инк. (Us) Получение производных 3-азабицикло [3.1.0] гексана
WO2005039580A1 (en) 2003-10-16 2005-05-06 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
EP2314571A3 (en) 2003-10-21 2011-08-31 CoLucid Pharmaceuticals, Inc. Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
DE602004028150D1 (de) 2003-11-26 2010-08-26 Pfizer Prod Inc Aminopyrazolderivate als gsk-3-inhibitoren
WO2005053701A1 (en) 2003-11-26 2005-06-16 Pfizer Products Inc. Combination of dopamine agonists and aralkyl and aralkylidene heterocyclic lactams and imides
US20050250803A1 (en) 2003-11-26 2005-11-10 Pfizer Inc Combination of dopamine agonists and monoamine reuptake inhibitors
MXPA06006026A (es) 2003-12-02 2006-08-23 Ucb Sa Derivados de imidazol, procesos para prepararlos y sus usos.
WO2005060949A2 (en) 2003-12-12 2005-07-07 Eli Lilly And Company Selective norepinephrine reuptake inhibitors for the treatment of hot flashes, impulse control disorders and personality change due to a general medical condition
US20050227980A1 (en) 2003-12-15 2005-10-13 Pfizer Inc. Aralkyl and aralkylidene heterocyclic lactam and imides
WO2005061491A2 (en) 2003-12-15 2005-07-07 Pfizer Products Inc. Aralkyl and aralkylidene heterocyclic lactams with affinity for 5-ht1 receptors
BRPI0417687A (pt) 2003-12-19 2007-04-03 Pfizer derivados de benzenossulfonilamino-piridin-2-ila e compostos relacionados como inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 (11-beta-hsd-1) para o tratamento de diabetes e obesidade
TW200522944A (en) 2003-12-23 2005-07-16 Lilly Co Eli CB1 modulator compounds
MXPA06007213A (es) 2003-12-23 2006-08-18 Pfizer Prod Inc Combinacion terapeutica para la mejora de la cognicion y trastornos sicoticos.
US20050171095A1 (en) 2004-01-06 2005-08-04 Pfizer Inc Combination of CRF antagonists and 5-HT1B receptor antagonists
ES2383115T3 (es) 2004-01-09 2012-06-18 Eli Lilly And Company Compuestos de tiofeno y furano
WO2005072713A2 (en) 2004-01-27 2005-08-11 The Feinstein Institute For Medical Research Cholinesterase inhibitors for treating inflammation
MXPA06008647A (es) 2004-01-29 2006-09-04 Pfizer Prod Inc Combinaciones de un antipsicotico atipico y derivados azabiciclicos aminometilpiridiloximetil/bencisoxazol para tratar trastornos del sistema nervioso central.
JP2007537151A (ja) 2004-01-29 2007-12-20 ファイザー・プロダクツ・インク γ−アミノ酪酸モジュレータと５−ＨＴ１Ｂ受容体アンタゴニストとの組合せ
WO2005074535A2 (en) 2004-01-30 2005-08-18 Eisai Co., Ltd. Cholinesterase inhibitors for spinal cord disorders
CA2555071A1 (en) 2004-02-02 2005-09-01 Pfizer Products Inc. Histamine-3 receptor modulators
RU2006129307A (ru) 2004-02-13 2008-02-20 Пфайзер Продактс Инк. (Us) Терапевтические комбинации атипичных нейролептиков с антагонистами кортикотропин-рилизинг фактора
JP2007522248A (ja) 2004-02-13 2007-08-09 ニューロモレキュラー・インコーポレイテッド てんかんおよび他のｃｎｓ障害の処置のための、ｎｍｄａレセプターアンタゴニストと抗てんかん薬との組み合わせ
US20050182044A1 (en) 2004-02-17 2005-08-18 Bruinsma Gosse B. Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate
ES2466641T3 (es) 2004-02-25 2014-06-10 Eli Lilly And Company 2,3,4,5-Tetrahidro-1H-benzo[d]azepinas 6-sustituidas como agonistas del receptor 5-HT2C
GB0405200D0 (en) 2004-03-08 2004-04-21 Pfizer Ltd Combinations comprising alpha-2-delta ligands
US20060148807A1 (en) 2004-03-12 2006-07-06 Pfizer Inc Pyrrolo[1,2b]pyridazine compounds and their uses
US20060166998A1 (en) 2004-03-12 2006-07-27 Pfizer Inc Pyrrolo[1,2-B]pyridazine compounds and their uses
WO2005090300A1 (en) 2004-03-17 2005-09-29 Pfizer Products Inc. Novel benzyl(idene)-lactam derivatives
JP2007529556A (ja) 2004-03-19 2007-10-25 アクソニクス インコーポレイテッド 認知障害の処置に有用なアセチルコリンエステラーゼ阻害剤およびｎ−メチル−ｄ−アスパラギン酸拮抗剤
WO2005100334A1 (en) 2004-04-14 2005-10-27 Pfizer Products Inc. Dipeptidyl peptidase-iv inhibitors
WO2005102272A2 (en) 2004-04-21 2005-11-03 Pfizer Products Inc. Sustained-release dosage forms for cabergoline
JP2007533740A (ja) 2004-04-22 2007-11-22 イーライ リリー アンド カンパニー Ｂａｃｅ阻害剤としてのアミド
US20050245543A1 (en) 2004-04-30 2005-11-03 Pfizer Inc Histamine-3 receptor antagonists
EP1753460A2 (en) 2004-05-11 2007-02-21 Pfizer Products Inc. Combination of atypical antipsychotics and 5-ht1b receptor antagonists
WO2005113535A2 (en) 2004-05-21 2005-12-01 Pfizer Products Inc. Pyrazinylmethyl lactam derivatives
WO2005113527A1 (en) 2004-05-21 2005-12-01 Pfizer Products Inc. Tetrahydronaphthyl- piperazines as 5-ht1b antagonists, inverse agonists and partial agonists
CA2569411A1 (en) * 2004-06-04 2005-12-22 Mood Management Sciences, Llc Methods and compositions for treating mood disorder
US20070212428A1 (en) * 2004-06-04 2007-09-13 Mood Management Sciences, Inc. Methods and compositions for treating mood disorder
AU2005251884B2 (en) 2004-06-11 2011-03-24 Ucb Process for preparing 2-oxo-1-pyrrolidine derivatives by intramolecular allylation
CA2571555A1 (en) 2004-06-22 2006-01-05 Pfizer Products Inc. Diazabicyclic histamine-3 receptor antagonists
MXPA06014473A (es) 2004-06-25 2007-03-01 Pfizer Prod Inc Piridil piperazinas para el tratamiento de trastornos de sistema nervioso central.
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
US7618980B2 (en) 2004-07-14 2009-11-17 Bristol-Myers Squibb Company Pyrrolo(oxo)quinolines as 5HT ligands
US20060014733A1 (en) 2004-07-19 2006-01-19 Pfizer Inc Histamine-3 agonists and antagonists
BRPI0513444A (pt) 2004-07-21 2008-05-06 Pfizer Prod Inc antagonistas do receptor da histamina 3
BRPI0513386A (pt) 2004-08-09 2008-05-06 Warner Lambert Co inibidores de reabsorção de norepinefrina de quinoxalinona para o tratamento de distúrbios do sistema nervoso central
WO2006024955A1 (en) 2004-09-01 2006-03-09 Pfizer Products Inc. Azabicyclic amine histamine-3 receptor antagonists
MX2007002460A (es) 2004-09-10 2007-05-04 Pfizer Prod Inc Metodos para tratar trastornos del humor utilizando derivados azabiciclicos de piridiloximetilo y benzisoxazol.
CA2580024A1 (en) 2004-09-10 2006-03-16 Pfizer Products Inc. Therapeutic diphenyl ether ligands
US20060063707A1 (en) 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
US20060069087A1 (en) 2004-09-27 2006-03-30 Pfizer Inc Histamine-3 receptor antagonists
EP1807087A2 (en) 2004-10-12 2007-07-18 Ernir Snorrason Inhibitors of acetylcholinesterase for treating skin diseases
JP2008516925A (ja) 2004-10-15 2008-05-22 ナームローゼ・フエンノートチヤツプ・オルガノン 双極性障害および随伴症状の治療
CA2584422A1 (en) 2004-10-18 2006-04-27 Eli Lilly And Company 1-(hetero)aryl-3-amino-pyrollidine derivatives for use as mglur3 receptor antagonists
EP1805160B1 (en) 2004-10-18 2011-04-06 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
WO2006060082A1 (en) 2004-10-22 2006-06-08 THE GOVERNMENT OF THE U.S.A. as represented by THE SEC., DEPT. OF HEALTH & HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH Tricyclic compounds, preparation thereof and use thereof as cholinesterase activity inhibitors
WO2006046131A1 (en) 2004-10-29 2006-05-04 Pfizer Products Inc. Tetralin histamine-3 receptor antagonists
WO2006048727A1 (en) 2004-11-02 2006-05-11 Pfizer Products Inc. Piperazinylphenalkyl lactam/amine ligands for the 5ht1b receptor
WO2006051407A1 (en) 2004-11-15 2006-05-18 Pfizer Products Inc. Azabenzoxazoles for the treatment of cns disorders
EP1814888A1 (en) 2004-11-15 2007-08-08 Pfizer Products Incorporated Azabenzoxazoles for the treatment of cns disorders
DK1828182T3 (da) 2004-11-29 2010-05-10 Warner Lambert Co Terapeutiske pyrazol[3,4-B]pyridiner og indazoler
ATE395348T1 (de) 2004-12-07 2008-05-15 Pfizer Prod Inc 1,2,3,3a;8,8a-hexahydro-2,7a- diazacyclopenta(a)inden-7-onderivate, die sich an neuronale nikotinische acetylcholinspezifische rezeptorstellen binden und zur modulation der cholinergen funktion und zur behandlung von suchterkrankungen eignen
EP1827468B1 (en) 2004-12-23 2012-08-22 Curaxis Pharmaceutical Corporation Acetylcholinesterase Inhibitors and leuprolide acetate for the treatment of Alzheimer's disease
EP1831172B1 (en) 2004-12-28 2009-02-18 Council of Scientific and Industrial Research Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors
US20060183763A1 (en) 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
JP4940152B2 (ja) 2005-01-05 2012-05-30 イーライ リリー アンド カンパニー パモ酸オランザピン二水和物
EA014249B1 (ru) 2005-01-27 2010-10-29 Алембик Лимитед Формуляция леветирацетама длительного высвобождения
FR2881618B1 (fr) 2005-02-10 2007-04-13 Centre Nat Rech Scient Utilisation de composes derives de pyrimidinetrione en tant qu'inhibiteurs de l'acetylcholinesterase, compositions contenant ces derives et leurs utilisations en tant qu'insecticides
WO2006086464A2 (en) 2005-02-10 2006-08-17 Bristol-Myers Squibb Company Dihydroquinazolinones as 5ht modulators
EP1853578A1 (en) 2005-02-15 2007-11-14 Eli Lilly And Company Substituted tetralins as selective estrogen receptor-beta agonists
US20070298098A1 (en) 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
WO2006123357A2 (en) 2005-02-22 2006-11-23 Sun Pharmaceutical Industries Limited Oral controlled release composition containing levetiracetam
WO2006090272A1 (en) 2005-02-22 2006-08-31 Warner-Lambert Company Llc Isoquinoline [1,8]naphthyridin-2-ones and related compounds for treatment of schizophrenia
WO2006090273A2 (en) 2005-02-22 2006-08-31 Warner-Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
EP1871363A4 (en) 2005-03-30 2009-01-21 Genpharm Inc COMBINED STAGE PROCESS FOR PHARMACEUTICAL COMPOSITIONS
EA200701856A1 (ru) 2005-04-01 2008-02-28 Уорнер-Ламберт Компани Ллс Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении
DE602006016934D1 (de) 2005-04-06 2010-10-28 Adamas Pharmaceuticals Inc Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
EP1869019B1 (en) 2005-04-08 2014-08-27 Pfizer Products Inc. Bicyclic [3.1.0] heteroaryl amides as type i glycine transport inhibitors
WO2006106416A1 (en) 2005-04-08 2006-10-12 Pfizer Products Inc. PYRIDIL-LACTAMS AND THEIR USE 5 -HTl RECEPTORS LIGAN
US20080305161A1 (en) 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
US7741358B2 (en) 2005-04-14 2010-06-22 N.V. Organon Crystal form of asenapine maleate
US20060241144A1 (en) 2005-04-20 2006-10-26 Albert Cha Method for treating apathy syndrome
US7456188B1 (en) 2005-04-28 2008-11-25 Bristol-Myers Squibb Company C-5 substituted quinazolinone derivatives as selective estrogen receptor beta modulators
JP2008542378A (ja) * 2005-05-31 2008-11-27 オレキシジェン・セラピューティクス・インコーポレーテッド 精神病性障害を管理する方法および組成物
EP2308867A3 (en) 2005-06-01 2011-10-19 UCB Pharma S.A. 2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses
EP1731149A1 (en) 2005-06-08 2006-12-13 Ucb S.A. Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
CA2607499C (en) 2005-06-22 2010-11-30 Pfizer Products Inc. Histamine-3 receptor antagonists
US20070015763A1 (en) 2005-07-12 2007-01-18 Pfizer Inc Treatment of psychosis associated with parkinson's disease and subcortical dementias using a combination of an atypical antipsychotic with a dopamine agonist
AU2006275694A1 (en) 2005-07-28 2007-02-08 Bristol-Myers Squibb Company Substituted tetrahydro-1H-pyrido(4,3,b)indoles as serotonin receptor agonists and antagonists
EP2682481A3 (en) 2005-08-03 2014-09-17 The Johns-Hopkins University Methods for characterizing and treating cognitive impairment in aging and disease
WO2007017750A1 (en) 2005-08-08 2007-02-15 Pfizer Products Inc. Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]pyridin-2-yl)-1,4-diaza-bicyclo[3.2.2]nonane
US7795436B2 (en) 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
GB0517740D0 (en) 2005-08-31 2005-10-12 Novartis Ag Organic compounds
WO2007026219A2 (en) 2005-08-31 2007-03-08 Pfizer Products Inc. Combinations of a 5-ht1b antagonist with a noradrenalin re-uptake inhibitor or a serotonin noradrenalin reutake inhibitor for treating cns conditions
ATE437859T1 (de) 2005-09-01 2009-08-15 Lilly Co Eli 6-substituierte- 2,3,4,5-tetrahydro-1h- benzoädüazepine als 5-ht2c-rezeptoragonisten
JP5249031B2 (ja) 2005-09-01 2013-07-31 イーライ リリー アンド カンパニー ５−ＨＴ２Ｃ受容体アゴニストとしての６−Ｎ結合型へテロ環置換された２，３，４，５−テトラヒドロ−１Ｈ−ベンゾ［ｄ］アゼピン
CA2619566C (en) 2005-09-01 2013-08-13 Eli Lilly And Company 6-substituted-2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists
PT1924561E (pt) 2005-09-01 2013-01-16 Lilly Co Eli Módulo de cabeça de impressão tendo uma fiada solta e controlador de impressora para lhe fornecer dados
US20090215857A1 (en) 2005-09-13 2009-08-27 Pfizer Products Inc. Therapeutic Pyrrolidines
US7745447B2 (en) 2005-10-26 2010-06-29 Bristol-Myers Squibb Company Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists
US8618115B2 (en) 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
WO2007057742A2 (en) 2005-11-18 2007-05-24 Pfizer Products Inc. Novel piperazinone derivatives
WO2007063385A2 (en) 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
JP2009518333A (ja) 2005-12-07 2009-05-07 ユセベ ファルマ ソシエテ アノニム キサンチン誘導体、その調製方法及びその使用
WO2007069053A1 (en) 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
NL2000397C2 (nl) 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
US20100222353A1 (en) 2006-01-27 2010-09-02 Pfizer Products Inc. Aminophthalazine derivative compounds
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
JP2009527542A (ja) 2006-02-23 2009-07-30 ファイザー・プロダクツ・インク Ｐｄｅ１０阻害薬としての置換キナゾリン
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007104035A1 (en) 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20090163482A1 (en) 2006-03-13 2009-06-25 Mchardy Stanton Furst Tetralines antagonists of the h-3 receptor
EP2001463B1 (en) 2006-03-20 2013-07-03 Council of Scientific and Industrial Research A pharmaceutical composition useful as acetyl cholinesterase inhibitors
US20070224636A1 (en) 2006-03-24 2007-09-27 Pfizer Inc Pyrrolo[1,2b]pyridazine compounds and their uses
EP2015750A2 (en) 2006-04-28 2009-01-21 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
US20090176829A1 (en) 2006-05-02 2009-07-09 Pfizer Inc Bicyclic heteroaryl compounds as pde10 inhibitors
US7858611B2 (en) 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
JP5214597B2 (ja) 2006-06-08 2013-06-19 ユセベ ファルマ ソシエテ アノニム ピロリジノンの共結晶
JP2009541481A (ja) 2006-06-26 2009-11-26 ファイザー・プロダクツ・インク Ｐｄｅ１０阻害剤としての三環式ヘテロアリール化合物
US20080014264A1 (en) 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
MX2009000508A (es) 2006-07-14 2009-01-27 Pfizer Prod Inc Sal tartrato de (7s)-7-[(5-fluoro-2-metil-bencil)oxi]-2-[(2r)-2-me tilpiperazin-1-il]-6,7-dihidro-5h-ciclopenta[b]piridina.
WO2008015516A1 (en) 2006-07-28 2008-02-07 Pfizer Products Inc. Fused tricyclic heterocycles for the treatment of schizophrenia
US20080045512A1 (en) 2006-08-09 2008-02-21 Pfizer Inc. Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]-pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane
WO2008020302A2 (en) 2006-08-17 2008-02-21 Pfizer Products Inc. Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
EP2051696A2 (en) 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
WO2008020306A2 (en) 2006-08-18 2008-02-21 Pfizer Products Inc. Isoindole derivatives
WO2008026046A1 (en) 2006-08-30 2008-03-06 Pfizer Products Inc. Morpholine d3 dopamine antagonists
CA2663189A1 (en) 2006-09-12 2008-03-20 Pfizer Products Inc. Benzimidazolone derivatives
WO2008062446A2 (en) 2006-09-14 2008-05-29 Alembic Limited An extended release composition of levetiracetam, which exhibits no adverse food effect
CA2664421A1 (en) 2006-09-22 2008-03-27 Braincells, Inc. Hmg coa reductase mediated modulation of neurogenesis
AR063497A1 (es) 2006-10-23 2009-01-28 Lilly Co Eli Compuesto de pirrodinil -2-ona, intermediario para la sintesis del mismo, composicion farmaceutica que lo comprende y su uso para preparar un medicamento
EP2420235A1 (en) 2006-10-27 2012-02-22 Medivation Neurology, Inc. Methods and combination therapies for treating alzheimer's disease
WO2008065500A2 (en) 2006-11-30 2008-06-05 Pfizer Products Inc. Heteroaryl amides as type i glycine transport inhibitors
US8247563B2 (en) 2006-12-11 2012-08-21 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors
WO2008074896A1 (en) 2006-12-21 2008-06-26 Prendergast Patrick T Compositions and methods for treatment of chronic neurological disorders
WO2008084324A1 (en) 2007-01-04 2008-07-17 Pfizer Products Inc. Naphthyridinone compound
JP4585610B2 (ja) 2007-01-22 2010-11-24 ファイザー・プロダクツ・インク 治療用化合物のトシル酸塩およびその医薬組成物
AU2008214380A1 (en) 2007-02-02 2008-08-14 Colucid Pharmaceuticals, Inc. Compounds that inhibit cholinesterase
FR2912056B1 (fr) 2007-02-05 2009-12-18 Rd Pharmagal Composition a liberation prolongee de levetiracetam et procede de preparation
WO2008095221A1 (en) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of adhd
EP2118112B1 (en) 2007-02-07 2015-07-08 Pfizer Inc. 3-amino-pyrrolo[3,4-c] pyrazole- 5 (1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors
CN101675052A (zh) 2007-04-12 2010-03-17 辉瑞大药厂 作为蛋白酶c抑制剂的3-酰氨基-吡咯并[3,4-c]吡唑-5(1h,4h,6h)甲醛衍生物
CN101687882A (zh) 2007-04-25 2010-03-31 百时美施贵宝公司 非碱性黑色素浓集激素受体-1拮抗剂
WO2008132139A2 (en) 2007-04-27 2008-11-06 Ucb Pharma S.A. New heterocyclic derivatives useful for the treatment of cns disorders
WO2008144305A1 (en) 2007-05-18 2008-11-27 Janssen Pharmaceutica N.V. Diaryl-substituted tetrahydroisoquinolines as histamine h3 receptor and serotonin transporter modulators
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
RU2339620C1 (ru) 2007-07-09 2008-11-27 Общество С Ограниченной Ответственностью "Фармвинг" Оксалат n, n-диметил-2-n, n-диметиламинометилпиридил-3-карбамат, обладающий антихолинэстеразной активностью и способностью улучшать когнитивные функции
WO2009011412A2 (en) 2007-07-13 2009-01-22 Eisai R & D Management Co., Ltd. Combination of ampa receptor antagonists and acetylcholinesterase inhibitors for the treatment of neuropathic pain
US20090030403A1 (en) 2007-07-27 2009-01-29 Leyde Kent W Methods and Systems for Attenuating the Tolerance Response to a Drug
KR20090031333A (ko) 2007-09-21 2009-03-25 주식회사 엘지생명과학 신규한 베타-세크리타제 저해용 화합물
US20090176740A1 (en) 2007-11-30 2009-07-09 Phillips Ii Dauglas James Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine
CA2708043C (en) 2007-12-07 2012-11-13 Pfizer Inc. Tosylate salt of trans-n-isobutyl-3-fluoro-3- [3-fluoro-4- (pyrrolidin-1-yl-methyl) -phenyl] cyclobut anecarboxamide
EP2254577A1 (en) * 2007-12-26 2010-12-01 Eisai R&D Management Co., Ltd. Ampa receptor antagonists for epilepsy, mental disorders or deficits in sensory organ
CN101925576B (zh) 2008-01-22 2013-02-06 伊莱利利公司 κ-选择性阿片受体拮抗剂
WO2009098576A1 (en) 2008-02-05 2009-08-13 Pfizer Inc. Pyridinyl amides for the treatment of cns and metabolic disorders
JP2011513360A (ja) 2008-03-03 2011-04-28 ユセベ ファルマ ソシエテ アノニム 医薬溶液、調製方法及び治療的使用
EP2276735A1 (en) 2008-04-17 2011-01-26 Pfizer Inc. Ether benzylidene piperidine aryl carboxamide compounds useful as faah inhibitors
CN102007121B (zh) 2008-04-22 2013-08-14 伊莱利利公司 作为cb-1配体的1，5-二苯基-吡咯烷-2-酮化合物
BRPI0910537A2 (pt) 2008-04-22 2015-09-29 Lilly Co Eli composto de 1,5-difenil-pirrolidin-2-ona como ligantes de cb-1
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
WO2010002869A1 (en) 2008-07-01 2010-01-07 Concert Pharmaceuticals, Inc. 2-oxo-1-pyrrolidine derivatives
JP2010024156A (ja) 2008-07-16 2010-02-04 Ucb Pharma Sa レベチラセタムを含む医薬組成物
TW201006801A (en) 2008-07-18 2010-02-16 Lilly Co Eli Imidazole carboxamides
US7932256B2 (en) 2008-07-31 2011-04-26 Bristol-Myers Squibb Company (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity
EP2331088A4 (en) 2008-08-06 2011-10-12 Gosforth Ct Holdings Pty Ltd COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES
CA2740610C (en) 2008-10-16 2020-01-07 The Johns Hopkins University Synaptic vesicle protein 2a inhibitors for treating age-related cognitive impairment
US20100113465A1 (en) 2008-10-30 2010-05-06 Pfizer Inc. 7-azaspiro[3.5]nonane-7-carboxamide compounds
US9125898B2 (en) 2008-11-14 2015-09-08 Neurotune Ag Acetam derivatives for pain relief
US20100125094A1 (en) 2008-11-17 2010-05-20 Auspex Pharmaceuticals, Inc. Pyrrolidinyl modulators of nicotinic acetylcholine receptors
DK2358360T3 (en) 2008-11-18 2016-12-12 Ucb Biopharma Sprl EXTENDED release formulations comprising one 2-OXO-1 PYRROLIDIN DERIVATIVE
WO2010058318A1 (en) 2008-11-21 2010-05-27 Pfizer Inc. 1-oxa-8-azaspiro [4, 5 ] decane- 8 -carboxamide compounds as faah inhibitors
US20100172979A1 (en) 2008-12-24 2010-07-08 Zhongshui Yu Controlled-release formulations
DK2391351T3 (da) 2009-01-29 2014-12-01 Ucb Pharma Sa Farmaceutisk sammensætning omfattende 2-oxo-1-pyrrolidinderivater
EP2393483B1 (en) 2009-02-09 2017-06-28 UCB Biopharma SPRL Pharmaceutical compositions comprising brivaracetam
EP2405913A1 (en) 2009-03-09 2012-01-18 Bristol-Myers Squibb Company Pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
US8278316B2 (en) 2009-03-09 2012-10-02 Bristol-Myers Squibb Company Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
WO2010111080A2 (en) 2009-03-27 2010-09-30 Eli Lilly And Company Optimized treatment of schizophrenia
US8846411B2 (en) 2009-06-11 2014-09-30 Microgenics Corporation Derivatives, reagents, and immunoassay for detecting levetiracetam
MX2011013870A (es) 2009-06-18 2012-02-01 Pfizer Compuestos biciclicos y triciclicos como inhibidores de quinurenina aminotransferasa ii.
US20120171125A1 (en) 2009-08-07 2012-07-05 Ucb Pharma, S.A. Methods for Enhancing the Cognitive Function
CN101647789B (zh) 2009-09-01 2011-08-17 天津药物研究院药业有限责任公司 左乙拉西坦缓释微丸胶囊制剂
WO2011049309A2 (ko) 2009-10-09 2011-04-28 영진약품공업 주식회사 속효성과 지속성을 동시에 갖는 약제학적 조성물
WO2011057199A1 (en) * 2009-11-06 2011-05-12 Adenios, Inc. Compositions for treating cns disorders
BR112012011710A2 (pt) 2009-11-16 2016-03-01 Lilly Co Eli composto de espiropiperidina como antagonistas de receptor de orl-1, sua composição farmacêutica e seu uso
UA107943C2 (xx) 2009-11-16 2015-03-10 Lilly Co Eli Сполуки спіропіперидину як антагоністи рецептора orl-1
JO2978B1 (en) 2009-12-21 2016-03-15 ايلي ليلي اند كومباني MGLU2 aids
CN102905532A (zh) * 2010-02-09 2013-01-30 约翰斯.霍普金斯大学 用于改善认知功能的方法和组合物
WO2011143721A1 (en) 2010-05-21 2011-11-24 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating neurodegenerative disorders
US8883812B2 (en) 2010-07-08 2014-11-11 Pfizer Inc. Piperidinyl pyrimidine amides as Kv7 potassium channel openers
CA2809217A1 (en) 2010-09-21 2012-03-29 Pfizer Inc. Pyrimidones for treatment of potassium channel related diseases
MX2013003832A (es) 2010-10-26 2013-10-01 Alpharma Pharmaceuticals Llc Formulaciones y metodos para atenuar la depresion respiratoria inducida por sobredosis de opioides.
KR20120055313A (ko) 2010-11-23 2012-05-31 주식회사 바이오파마티스 레베티라세탐 또는 이의 약학적으로 허용되는 염을 포함하는 용출 안정성이 개선된 서방형 약학 조성물 및 이의 제조방법
KR101522803B1 (ko) 2010-12-01 2015-05-26 화이자 인코포레이티드 Kat ii 억제제
CN103228660A (zh) 2010-12-01 2013-07-31 辉瑞大药厂 Kat ii 抑制剂
CN109662961A (zh) 2011-02-09 2019-04-23 约翰斯霍普金斯大学 用于改善认知功能的方法和组合物
PH12013501556A1 (en) 2011-02-23 2017-10-25 Pfizer IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
DE102011103270A1 (de) 2011-05-26 2012-11-29 Stada Arzneimittel Ag Pulverförmige Mischung zur Herstellung von Levetiracetam-haltigen Tabletten
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
HK1215170A1 (zh) 2012-11-14 2016-08-19 The Johns Hopkins University 治療精神分裂症的方法和組合物
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2014144546A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositons for improving cognitive function
EA034167B8 (ru) 2015-05-22 2021-04-27 Эйджинбайо, Инк. Фармацевтические композиции леветирацетама пролонгированного высвобождения

Also Published As

Publication number Publication date
JP2018090609A (ja) 2018-06-14
JP2015537003A (ja) 2015-12-24
WO2014078568A1 (en) 2014-05-22
EP2919788A4 (en) 2016-05-25
US20140206667A1 (en) 2014-07-24
CA2891122A1 (en) 2014-05-22
EP2919788A1 (en) 2015-09-23
US10154988B2 (en) 2018-12-18
EP3610890A1 (en) 2020-02-19
US20180125818A1 (en) 2018-05-10
CA2891122C (en) 2021-07-20
US10624875B2 (en) 2020-04-21
JP6440625B2 (ja) 2018-12-19
US20150313876A1 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
HK1215170A1 (zh) 治療精神分裂症的方法和組合物
CL2013002125A1 (es) Compuestos derivados de imidazo[5,1-f][1,2,4]triazinas; composicion farmaceutica; y uso en el tratamiento del deterioro cognitivo asociado con esquizofrenia.
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
CL2015002516A1 (es) Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y métodos de uso
MX361183B (es) Derivados de 1,4-ciclohexilamina y procesos para la preparación de los mismos.
TW201129565A (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof
EP2855687A4 (en) MICROORGANISMS AND METHOD FOR PRODUCING 4-HYDROXYBUTYRATE, 1,4-BANDEDIOL AND RELATED COMPOUNDS
UY34792A (es) ?método de uso de profungicidas de uk-2a para control de la roya de soja?.
UY33925A (es) Inhibidores tricíclicos de quinasas
EA201071234A1 (ru) Производные изохинолинона в качестве nk3 антагонистов
EP2578626A4 (en) RUBBER COMPOSITION FOR TIRE INSULATIONS AND TIRES THEREWITH
EP2799467A4 (en) MANUFACTURING METHOD FOR A RUBBER COMPOSITION, RUBBER COMPOSITION AND AIR TIRES THEREWITH
CL2013001591A1 (es) Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades.
CL2012003427A1 (es) Compuestos derivados de 5-amino-3,6-dihidro-1h-pirazina-2-ona; y uso en el tratamiento de enfermedades tales como alzheimer, senilidad, demencia, entre otras.
GB201507052D0 (en) Trimaran having outriggers with propulsors
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
CL2014002334A1 (es) Compuestos derivados de indanos espirofusionados, inhibidores de la beta-secretasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como deterioro cognitivo, trastornos neurodegenerativos, demencia, entre otras.
CO6801738A2 (es) Composición oftálmica de alta concentración de olopatadina
PH12015501609A1 (en) Phenicol antibacterials
WO2012085557A3 (en) Methods and biomarkers for differentially diagnosing psychotic disorders
BR112013024099A2 (pt) pegador de mão ergonômico tendo estrias assimétricas
IN2015KN00073A (zh)
CO6660435A2 (es) Una forma cristalina de clorhidrato de (r) -7- cloro-n- (quinuclidin -3-il)benzo[b] tiofeno-2- carboxamida monohodratado
CL2014000641A1 (es) Compuestos derivados de triazolo[1,5-a]piridina, inhibidores de la ped10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de enfermedades tales como esquizofrenia, parkinson, alzheimer, entre otras.
FR2983097B1 (fr) Machine-outil pour l&#39;usinage de pieces en forme d&#39;arbres